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Abstract
Background
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Medications licensed for the treatment of dementia have limited efficacy against
cognitive impairment or against the distressed behaviours (behavioural and
psychological symptoms, or behaviour that challenges) which are also often the most
distressing aspect of the disorder for caregivers. Complementary therapies, including
aromatherapy, are attractive to patients, practitioners and families, because they are
perceived as being unlikely to cause adverse effects. Therefore there is interest in
whether aromatherapy might offer a safe means of alleviating distressed behaviours
in dementia.
Objectives
To assess the efficacy and safety of aromatherapy for people with dementia.
Search methods
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group
Specialized Register, on 5 May 2020 using the terms: aromatherapy, lemon,
lavender, rose, aroma, alternative therapies, complementary therapies, essential oils.
In addition, we searched MEDLINE, Embase, PsycINFO (all via Ovid SP), Web of
Science Core Collection (via Thompson Web of Science), LILACS (via BIREME),
CENTRAL (via the Cochrane Library), ClinicalTrials.gov and the WHO trials portal
(ICTRP) on 5 May 2020.
Selection criteria
We included randomised controlled trials which compared fragrance from plants in
an intervention defined as aromatherapy for people with dementia with placebo
aromatherapy or with treatment as usual. All doses, frequencies and fragrances of
aromatherapy were considered. Participants in the included studies had a diagnosis
of dementia of any subtype and severity.
Data collection and analysis
Two reviewers independently selected studies for inclusion, extracted data and
assessed risk of bias in included studies, involving other authors to reach consensus
decisions where necessary. We did not perform any meta-analyses because of
heterogeneity between studies, but presented a narrative synthesis of results from
the included trials. Because of the heterogeneity of analysis methods and
inadequate or absent reporting of data from some trials, we used statistical
significance (p value ≤ or > 0.5) as a summary metric when synthesising results
across studies. As far as possible, we used GRADE methods to assess our
confidence in the results of the trials, downgrading for risk of bias and imprecision.
Main results
We included 13 studies with 708 participants. All participants had dementia and in
the 12 trials which described the setting, all were resident in institutional care
facilities. Nine trials recruited participants because they had significant agitation or
other behavioural and psychological symptoms in dementia (BPSD) at baseline. The
fragrances used were lavender (eight studies); lemon balm (four studies); lavender
and lemon balm, lavender and orange, and cedar extracts (one study each). For six
trials, assessment of risk of bias and extraction of results was hampered by poor
reporting. Four of the other seven trials were at low risk of bias in all domains, but all
were small (range 18-186 participants; median 66), reducing our confidence in the
results. Our primary outcomes were agitation, overall behavioural and psychological
symptoms, and adverse effects. Ten trials assessed agitation using various scales.
Among the five trials for which our confidence in the results was moderate or low,
8/17/2020 Cochrane Dementia and Cognitive Improvement Group: Aromatherapy for dementia
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fversion%3Dz2007011022199407474470262434096… 3/87
four trials reported no significant effect on agitation and one trial reported a
significant benefit of aromatherapy. The other five trials either reported no useable
data or our confidence in the results was very low. Eight trials assessed overall
BPSD using the Neuropsychiatric Inventory and we had moderate or low confidence
in the results of five of them. Of these, four reported significant benefit from
aromatherapy and one reported no significant effect. Adverse events were poorly
reported or not reported at all in most trials. No more than two trials assessed each
of our secondary outcomes of quality of life, mood, sleep, activities of daily living,
caregiver burden. We did not find evidence of benefit on these outcomes. Three
trials assessed cognition, one did not report any data and the other two trials
reported no significant effect of aromatherapy on cognition; our confidence in the
results of these studies was low.
Authors' conclusions
We have not found any convincing evidence that aromatherapy (or exposure to
fragrant plant oils) is beneficial for people with dementia although there are many
limitations to the data. Conduct or reporting problems in half of the included studies
meant that they could not contribute to the conclusions. Results from the other
studies were inconsistent. Harms were very poorly reported in the included studies.
In order for clear conclusions to be drawn, better design and reporting and
consistency of outcome measurement in future trials would be needed.
Plain language summary
Aromatherapy for dementia
Background to the review
Medication prescribed for the treatment of dementia is not always effective at
relieving symptoms of the condition such as problems with thinking, behaviour,
mood, and sleep. Natural therapies, including aromatherapy (the use of fragrant
essential oils from plants), are attractive options for treating these distressing
symptoms of dementia as they are often thought to have a low risk of side effects.
Review question
Is aromatherapy safe and effective at relieving symptoms of dementia?
What we did
We searched the medical literature up to 5 May 2020, looking for studies which
compared aromatherapy for people with dementia to a control treatment, which could
be either usual care or ‘dummy’ aromatherapy involving a non-fragrant oil. To make
the comparison fair, the studies had to assign people randomly to aromatherapy or to
the control treatment. We looked at the effect on agitation, behavioural and mental
health issues, and other important symptoms of dementia. We also looked for reports
of side effects. Because the studies were so different from each other, we were not
able to combine results statistically so we described the results of individual studies
and assessed how confident we could be in them.
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Study characteristics
We found 13 studies to include in the review. There were 708 participants in total. All
had dementia and were living in care homes. The most commonly used
aromatherapy fragrance was lavender. Studies also used lemon balm, orange and
cedar extracts.
Main findings
Ten studies assessed agitation, but five did not report data we could use or our
confidence in their results was very low. We had moderate or low confidence in the
results of the other five: four reported no significant effect of aromatherapy and one
reported a significant benefit. Eight studies assessed behavioural and mental health
issues, but three did not report any usable data, or our confidence in the results was
very low. Of the other five, for which our confidence was moderate or low, four
reported a significant benefit from aromatherapy and one reported no significant
effect. Side effects of treatment were either poorly reported or not reported at all. No
more than three studies reported our secondary outcomes which were quality of life,
cognition (thinking), mood, sleep, activities of daily living, and caregiver burden. We
found no evidence that aromatherapy was helpful for any of these outcomes.
Quality of the evidence
Overall the quality of the evidence was poor. Many of the studies were poorly
reported and some did not report any data we could use. Most studies were very
small so that there was a lot of uncertainty about their results. Results of different
studies did not agree with one another.
Conclusions
We have found no convincing evidence that aromatherapy is beneficial for people
with dementia although there are many limitations to the data reported by the studies
so conclusions cannot be drawn with confidence. In order to determine whether
aromatherapy is safe and effective at relieving symptoms of dementia, larger, well
designed studies with clearer reporting are needed.
Summary of findings
Summary of findings 1
Aromatherapy versus control (placebo aromatherapy / no intervention)
for dementia
Aromatherapy versus control (placebo aromatherapy / no intervention) for dementia
Patient or population: Dementia
Setting: Care facilities or hospital wards
Intervention: Aromatherapy
Comparison: Control (placebo aromatherapy / no intervention)
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Five trials provided either no usable data or data in which our
confidence was very low. Of the remaining five trials, four
reported no statistically significant effect on agitation and one















range 2 to 12
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Three trials provided either no useable data or data in which
our confidence was very low. Of the remaining five trials, four
trials reported a significant reduction in overall behavioural
and psychological symptoms and one trial did not find a
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Adverse effects were reported in only four of twelve trials.
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One trial reported a significant beneficial effect of
aromatherapy on quality of life. The other trial did not find
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One trial reported no significant effect of aromatherapy on
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GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the
effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to
be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially
different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to
be substantially different from the estimate of effect
1 Inconsistency: downgraded by 1 level due to inconsistent findings.
2 Risk of bias: downgraded by 1 level due to study limitations. Random sequence generation
(selection bias): low risk of bias in 6 studies, unclear risk of bias in four studies. Allocation
concealment (selection bias): low risk of bias in six studies, unclear risk of bias in four studies.
Blinding of participants and personnel (performance bias): low risk of bias in six studies, unclear risk
of bias in three studies, high risk of bias in one study. Blinding of outcome assessment (detection
bias): low risk of bias in eight studies, unclear risk of bias in one study, high risk of bias in one study.
Incomplete outcome data: low risk of bias in eight studies, unclear risk of bias in one study, high risk of
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bias in one study. Selective reporting (reporting bias): low risk of bias in seven studies, high risk of
bias in three studies. Other bias: low risk of bias in nine studies, unclear risk of bias in one study.
3 Imprecision: downgraded by two levels due to small sample size in all studies.
4 Publication bias: downgraded by one level because included studies did not publish usable data on
outcomes they measured.
5 Risk of bias: downgraded by one level due to study limitations. Random sequence generation
(selection bias): low risk of bias in four studies, unclear risk of bias in four studies. Allocation
concealment (selection bias): low risk of bias in four studies, unclear risk of bias in four studies.
Blinding of participants and personnel (performance bias): low risk of bias in five studies, unclear risk
of bias in one study, high risk of bias in two studies. Blinding of outcome assessment (detection bias):
low risk of bias in five studies, unclear risk of bias in two studies, high risk of bias in one study.
Incomplete outcome data (attrition bias): low risk of bias in four studies, unclear risk of bias in two
studies, high risk of bias in two studies. Selective reporting (reporting bias): low risk of bias in seven
studies, high risk of bias in one study. Other bias: low risk of bias in seven studies, high risk of bias in
one study.
6 Risk of bias: Ballard 2002 and Burns 2011 were at low risk of bias in all domains.
7 Indirectness: downgraded by one level due to Ballard 2002 using Dementia Care Mapping to assess
quality of life which we consider to be an indirect measure.
8 Risk of bias: downgraded by one level due to study limitations. Random sequence generation
(selection bias): low risk of bias in one study, unclear risk of bias in one study. Allocation concealment
(selection bias): low risk of bias in one study, unclear risk of bias in one study. Blinding of participants
and personnel (performance bias): low risk of bias in one study, unclear risk of bias in one study.
Blinding of outcome assessment (detection bias): low risk of bias in both studies. Incomplete outcome
data (attrition bias): low risk of bias in both studies. Selective reporting (reporting bias): low risk of bias
in one study, high risk of bias in one study. Other bias: low risk of bias in both studies.
9 Risk of bias: downgraded by one level due to study limitations. Random sequence generation
(selection bias): unclear risk of bias. Allocation concealment (selection bias): unclear risk of bias.
Blinding of participants and personnel (performance bias): low risk of bias. Blinding of outcome
assessment (detection bias): low risk of bias. Incomplete outcome data (attrition bias): high risk of
bias. Selective reporting (reporting bias): low risk of bias. Other bias: high risk of bias.
10 Risk of bias: downgraded by one level due to study limitations. Random sequence generation
(selection bias): low risk of bias in one study, unclear risk of bias in one study. Allocation concealment
(selection bias): low risk of bias in one study, unclear risk of bias in one study. Blinding of participants
and personnel (performance bias): low risk of bias in one study, high risk of bias in one study. Blinding
of outcome assessment (detection bias): low risk of bias in both studies. Incomplete outcome data
(attrition bias): low risk of bias in both studies. Selective reporting (reporting bias): low risk of bias in
both studies. Other bias: low risk of bias in both studies.
Background
Description of the condition
Dementia is a condition in which acquired cognitive impairment is severe enough to
affect a person's ability to manage everyday activities. Usually it occurs in later life
and is caused by progressive, neurodegenerative conditions, of which the most
common are Alzheimer's disease and cerebrovascular disease. The cognitive
deficits are often accompanied by psychiatric and behavioural symptoms, such as
apathy, mood changes and, especially in the later stages of the illness, agitated
behaviours (such as restlessness, shouting or physical aggression to carers) which
may be expressions of distress (Kales 2015). Dementia is devastating both to the
person directly affected and to families, who undertake most of the care for people
with dementia and who experience high levels of distress and burden (Cheng 2017).
In high income countries it is estimated that 34% of patients with severe dementia
are cared for in residential or nursing facilities (Prince 2015).
Dementia is a major healthcare challenge with an estimated 50 million people
worldwide suffering from the condition and nearly 10 million new cases every year
(WHO 2017). This creates an enormous challenge for informal and professional care
systems. Currently, there are no medical treatments which can prevent or alter the
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course of any form of dementia. The licensed medications which are available have
limited efficacy against cognitive symptoms and little or no effect on the distressed
behaviours (behavioural and psychological symptoms, or behaviour that challenges)
which often present the greatest burden to caregivers (Battle 2019; Birks 2018;
McShane 2019; Birks 2006; Birks 2015). Other medications which are used for
behavioural and psychological symptoms in dementia (BPSD) also have limited
efficacy and have been associated with significant adverse effects (Reus 2016).
NICE guidelines recommend non-pharmacological strategies should be considered
(NICE 2018). Many people with dementia and their carers use complementary and
alternative therapies, but there is a lack of high quality research to guide their use
(Alzheimer's Society 2014).
In the context of aromatherapy, it is pertinent to note that people with dementia have,
as a population, a greater prevalence of olfactory impairment (impaired sense of
smell) and that this may be a very early sign of some of the neurodegenerative
diseases associated with cognitive decline (Bathini 2019).
Description of the intervention
Complementary (or alternative) therapies are popular approaches to a wide range of
health problems. There is evidence to show that complementary medicine use is a
substantial and growing part of healthcare behaviour in Europe, Australia and North
America (Harris 2012). Aromatherapy is one of the main complementary therapies
practised by nurses and other healthcare professionals in hospital, hospice, and
community settings (Buckle 2003).
Aromatherapy is a part of the discipline of phytotherapy (the use of whole plants or
parts of plants for medicinal purposes) and uses pure essential oils from fragrant
plants (such as lavender (Lavandula angustifolia), lemon balm (Melissa officinalis),
peppermint, sweet marjoram, and rose) to help relieve health problems and improve
quality of life in general (OnHealth 2000). Essential oils have been defined as "highly
fragrant essences extracted from plants by distillation, which evaporate readily"
(Tisserand 1988). They may be applied directly to the skin or vaporised and
administered through inhalation only.
Essential oils are many and varied, with presumed different potential effects. These
are claimed to include promotion of relaxation and sleep, relief of pain, reduction of
agitation and depressive symptoms (for example Halycon 2000). Aromatherapy
might be of particular use as an intervention for people who are confused, have little
or no preserved language function, or for whom verbal interaction is difficult, and for
whom conventional medicine is seen as being of only marginal benefit.
Aromatherapy has, therefore, been used to address behavioural and psychological
symptoms in dementia, aiming for example to reduce disturbed behaviour (Brooker
1997; Lin 2007; Nguyen 2008), promote sleep (Wolfe 1996; Hwang 2015), and
stimulate motivated behaviour (MacMahon 1998).
Essential oils selected for aromatherapy have been reported to have very low toxicity
profiles and, if administered by qualified practitioners, have been presented as safer
than conventional pharmacological medications (Perry 2006). However, common
assumptions about the safety of aromatherapy have been questioned. A review of
published case reports and case series found that aromatherapy has potential to
cause adverse effects, some serious, and commented that the frequency of such
effects is unknown (Posadzki 2012).
While pharmacological medications are highly standardised, extraction techniques
for essential oils are variable across manufacturers (Barnes 2003). Other factors,
such as agricultural, storage and processing factors, can also influence the content
and concentration of constituents (Barnes 2003). However, there are established
systems of quality control (Shinde 2009; Turek 2013) and some manufacturers
produce standardised extracts to achieve within-manufacturer consistency, similar to
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pharmaceutical quality (Barnes 2003). The 'dose' delivered to each person also
depends on the mode of delivery, the volume of oil, temperature, room size and air
flow. Complete standardisation of treatments is therefore hard to achieve.
How the intervention might work
The essential oils used in aromatherapy are most commonly delivered through
electric diffusers and vaporizers or massaged into the skin, thus the oil evaporates
and the aroma stimulates the olfactory sense (Kong 2009). The aromas used are
generally experienced as pleasant and so the immediate effect may be a positive
emotional response. It has also been suggested that olfactory sensations may be
effective means of stimulating implicit memories (Degel 2001). Although deterioration
of explicit memory is a prominent symptom of dementia, there is evidence to suggest
that implicit memory can remain intact in patients with the disease (Fleischman
2005). The implicit memory may include an emotional response based on the
person's past experience (Holmes 2004). Some authors have also suggested
pharmacological actions of essential oils, e.g. relating to inhibition of
acetylcholinesterase (Arruda 2012).
Why it is important to do this review
Currently, guidelines issued by the National Institute for Clinical Excellence (NICE
2018) in the UK recommend that aromatherapy may be considered to promote well
being in people with dementia. Despite such recommendations and an increase in
popularity, the rationale for aromatherapy is based on limited scientific research, with
the majority of evidence coming from studies at high risk of bias (case series,
uncontrolled studies, etc). Additionally, despite the implementation of regulatory
processes such as the European Directive on Traditional Herbal Medicinal Products
(Directive 2004/24/EC), the absence of a regulatory body to approve the
manufacturing practice of unlicensed products such as essential oils makes it
impossible to identify those that reach acceptable standards. Hence uncertainties
about both efficacy and safety remain. This review aims to address these
uncertainties by identifying and synthesising the best available evidence.
Objectives
To assess the efficacy and safety of aromatherapy for people with dementia.
Methods
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) only.
Types of participants
Participants in the included studies had a diagnosis of dementia of any type and
severity. We accepted formal diagnoses based on criteria such as the International
Classification of Diseases-10 (ICD-10) (WHO 1993) and Diagnostic and Statistical
Manual of Mental Disorders fourth Edition (DSM-IV) (APA 1994), or clinical
diagnoses, or cognitive test scores consistent with dementia on well-validated
assessment scales for cognitive function, such as the Mini-Mental State Examination
(MMSE) (Folstein 1975) and the Alzheimer's Disease Assessment Scale-cognitive
subscale (ADAS-Cog) (Rosen 1994).
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Types of interventions
We included trials which used fragrance from plants in an intervention defined as
aromatherapy for people with dementia. There were no restrictions on fragrance,
dose, frequency or duration of treatment.
The comparator group was placebo aromatherapy or treatment as usual / no
treatment.
Types of outcome measures
Primary outcomes
1. Agitation
2. Overall behavioural and psychological symptoms (BPSD)
3. Adverse effects
Secondary outcomes




5. Activities of daily living
6. Caregiver burden or distress, or both
Summary of findings table
We used the GRADE approach to assess the overall quality of evidence behind each
result (Schünemann 2008) and used the GRADE profiler to import data from Review
Manager (RevMan) to create 'Summary of findings' tables. These tables provide
outcome-specific information concerning the overall quality of evidence from each
included study in the comparison, the magnitude of effect of the intervention
examined, and the sum of available data on the outcomes that we rated as most
important to patient care. We selected the following outcomes for inclusion in the
summary of findings tables:
1. Agitation.
2. Overall behavioural and psychological symptoms.
3. Adverse effects.
4. Quality of life.
5. Activities of daily living.
6. Mood.
7. Sleep.
Search methods for identification of studies
Electronic searches
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group
Specialised Register, on 5 May 2020. The search terms used were: aromatherapy,
lemon, lavender, rose, aroma, alternative therapies, complementary therapies,
essential oils.
ALOIS is maintained by the Information Specialists of the Cochrane Dementia and
Cognitive Improvement Group and contains studies in the areas of dementia
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prevention, dementia treatment, and cognitive enhancement in healthy individuals.
The studies are identified from:  
1. monthly searches of a number of major healthcare databases: MEDLINE,
Embase, CINAHL, PsycINFO, and LILACS;
2. monthly searches of a number of trial registers: International Standard
Randomised Controlled Trial Number (ISRCTN); the World Health Organization
(WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical
Trials Register; the German Clinical Trials Register; the Iranian Registry of
Clinical Trials; and the Netherlands National Trials Register; plus others);
3. quarterly search of the Central Register of Controlled Trials (CENTRAL) in The
Cochrane Library;
4. six-monthly searches of a number of grey literature source: ISI Web of Science
Conference Proceedings.
Details of the search strategies used for the retrieval of reports of trials from the
healthcare databases, CENTRAL and conference proceedings can be viewed in the
‘methods used in reviews’ section within the editorial information about the Dementia
and Cognitive Improvement Group.
We performed additional searches in many of the sources listed above to ensure that
the search for the review was as up-to-date and as comprehensive as possible. The
search strategies we used can be seen Appendix 1.
Electronic searches carried out in the previous versions of the review can be viewed
in Appendix 2 and Appendix 3.
Searching other resources
We searched reference lists of included trials for additional studies.
Data collection and analysis
Selection of studies
For the original review, LTF and AS independently screened the titles and abstracts
extracted by the searches for their eligibility for potential inclusion in the review
based on the above criteria, this was discussed with MO.
For the 2008 update, FEH and TPHB assessed the new study found by the March
2008 search using the same criteria as previously used.
For the 2014 update, NM and KSW independently screened 28 studies, again using
the same criteria as previously used.
For the 2020 update, BO-B, AG and ELB independently screened titles and
abstracts. BO-B, AG, ELB, SDS, JH and JMcC all contributed to full text screening.
At least two authors independently assessed the papers and we resolved
disagreements by discussion with the full author team.
Data extraction and management
We extracted the data from the published reports. At least two authors independently
extracted the data and we resolved disagreements by discussion with the full author
team.
Assessment of risk of bias in included studies
For the original review, NM undertook assessment of the risk of bias of all the
included trials according to the methods in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) and KSW checked these. For the 2020
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update, this was reviewed by ELB, BO-B, JH, SDS and JMcC and the authors added
the risk of bias for the newly included studies.
The risk of bias tool examines five key domains for bias: selection bias, performance
bias, attrition bias, detection bias, and reporting bias. Each domain was assessed
and classified as either a low or a high risk of bias, and where insufficient detail was
reported in a study to assess the risk this was reported as 'unclear'. In addition, we
reported any other risk of bias noted in the study.
We used the Cochrane 'Risk of bias' tool in RevMan 5.3 (RevMan 2014).
Measures of treatment effect
All outcomes in the review are continuous measures. We used the mean difference
(MD) between groups and its 95% confidence interval (CI) as the measure of
treatment effect.
Unit of analysis issues
Where studies used a crossover method, we intended to extract paired data. These
were not available in any of the reports of the included crossover trials so we
reported results based on analyses of unpaired data, recognising that this reduces
the power of the study to detect an effect.
Where studies reported outcomes at more than one time point, we used the outcome
data from the end of the intervention period where possible. A few studies reported
data which summarised effects throughout the intervention period and we also
included these.
Dealing with missing data
We reported the amount of missing outcome data in each trial. When reporting
triallists' own analyses, we favoured intention-to-treat analyses and reported any
imputation methods.
Assessment of heterogeneity
We assessed clinical heterogeneity between studies, considering the participants,
characteristics of the intervention, and the outcomes reported.
Assessment of reporting biases
There was insufficient data for formal assessment of reporting biases.
Data synthesis
We considered the studies unsuitable for meta-analysis because of clinical diversity,
the heterogeneity of analysis methods and inadequate or absent reporting of
outcome data from some trials. For these reasons, we presented a narrative review
of the results, using statistical significance (p value ≤ or > 0.5) as a summary metric
when synthesising results across studies.
Subgroup analysis and investigation of heterogeneity
We did not undertake any subgroup analyses.
Sensitivity analysis
We did not undertake any sensitivity analyses.
Summary of findings and assessment of the certainty of the
evidence




See Characteristics of included studies and Characteristics of excluded studies for
details of the studies considered for this review.
Results of the search
Searches up to and including May 2020 identified 3649 records. One record was
identified through forward citation and one record through other sources. After
duplicates were removed, 2358 records remained. CDCIG information specialists
were able to identify 1818 as irrelevant. Review authors screened 540 titles or
abstracts and selected 71 to be assessed in full text. 43 records were excluded (see
Characteristics of excluded studies); two ongoing trials were identified from trial
registry entries (see Characteristics of ongoing studies); six further trials, also
described in trial registry entries, and one published study are awaiting classification
while additional information is sought about eligibility from trial authors (see
Characteristics of studies awaiting classification). 13 trials, described in 19 records,
were included in the current update (see Characteristics of included studies); seven
of these trials were included in the last version of the review in 2014. The process of
study selection is summarised in Figure 1.
Included studies
We included 13 studies with 708 participants (Ballard 2002; Burns 2011; Cameron
2011; Fu 2013; Fujii 2008; Hanson 2013; Lin 2007; O'Connor 2013; Smallwood
2001; Takahashi 2020; Yang 2015; Yang 2016; Watson 2019). One study was
described only in a conference poster (Hanson 2013). For the 2014 version of this
review, additional unpublished data was provided by the authors of Ballard 2002.
1. Study design
All trials were RCTs. Eleven trials randomised individuals and two were cluster-RCTs
(Ballard 2002 and Yang 2015) with residential care facilities as the unit of
randomisation. In Ballard 2002 eight nursing homes were matched in pairs and
within each pair homes were allocated randomly to active treatment or control.
Similarly, Yang 2015 included three retirement homes in each of two categories:
veterans' homes and other long-term care facilities. When a veteran's home was
randomly assigned to either the aroma-acupressure, aromatherapy, or control
condition, a long-term care facility was also assigned to this condition. Five trials
used a crossover design (Cameron 2011, Hanson 2013, Lin 2007, Watson 2019 and
O'Connor 2013). Hanson 2013 had no washout period between treatments. The
other crossover trials used washout periods ranging from four days to two weeks in
length.
2. Setting
Lin 2007 was conducted in Hong Kong; Yang 2015 and Yang 2016 were both based
in Taiwan; Fujii 2008 and Takahashi 2020 were conducted in Japan. Fu 2013;
Watson 2019 and O'Connor 2013 were based in Australia; Hanson 2013 was
conducted in Minnesota, United States and the remaining four studies were based in
the UK.
Participants in 12 trials were resident in institutions, which were described in different
ways. Ballard 2002 and Burns 2011 included residents in specialist nursing homes,
Fu 2013 and Yang 2016 included participants from long term care facilities, Yang
2015 included participants from three long-term care facilities and three retirement
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homes for veterans, Hanson 2013 recruited participants from memory care units in
an assisted living facility, Lin 2007 was conducted in a 'care and attention home',
O'Connor 2013 recruited participants from eight specialist psychogeriatric nursing
homes and three private nursing homes, Smallwood 2001 included inpatients in a
district general hospital ward, Fujii 2008 included patients in long-term care in a
hospital, Cameron 2011 included inpatients but did not report the setting, Watson
2019 included patients from 6 residential aged care facilities. One trial (Takahashi
2020) did not report the setting.
3. Participants
In 11 studies, all participants were identified as having dementia. Nine of these trials
also specified that participants should be exhibiting agitation or other BPSD at
baseline. Hanson 2013 provided no information about participant diagnoses but
recruited from memory care units in an assisted living facility. Watson 2019 included
participants with and without dementia, but in this review we consider only the 56
participants with dementia. The mean age of participants included in the studies
ranged from 66.8 years (Smallwood 2001) to 85.7 years (Hanson 2013) (no data
from Cameron 2011). The mean age of all participants in Watson 2019 was 89.3
years, but demographic data was not provided separately for participants with
dementia. The percentage of female participants was approximately 59% (no data
from Cameron 2011 or from Watson 2019 for participants with dementia).
Ballard 2002 included 72 people with severe dementia, diagnosed with the Clinical
Dementia Rating scale (Hughes 1982), and clinically significant agitation.
Burns 2011 included 114 participants with a National Institute of Neurological and
Communicative Disorders and Stroke and Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) diagnosis of probable or possible
Alzheimer’s disease and agitation, 63 participants were randomised to the two
groups included in this review.
In Cameron 2011 the 18 participants had moderate to severe dementia and
'behavioural and psychological symptoms in dementia' (BPSD); they did not report
the diagnostic criteria.
Fu 2013 included 67 participants with cognitive functional impairment indicative of a
dementia condition and features of Alzheimer’s disease according to the American
Psychiatric Association DSM-IV-TR, with a documented history of agitation or
aggression.
Fujii 2008 included 28 participants with dementia diagnosed according to DSM-IV
criteria.
Hanson 2013 included 22 participants but did not specify the participant inclusion
criteria in the poster or abstract.
In Lin 2007, the participants were 70 Chinese older persons with dementia
diagnosed according to the DSM-IV and with clinically significant agitation (Chinese
CMAI). The causes of dementia were reported as Alzheimer's disease, vascular and
other unstated dementias.
O'Connor 2013 included 66 participants with at least mild dementia on the Clinical
Dementia Rating scale and physically agitated behaviour not due primarily to pain,
physical illness, depression, or psychosis.
Smallwood 2001 included 21 patients with a clinical diagnosis of severe dementia
made by a psychiatrist.
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Takahashi 2020 included 36 patients with a clinical diagnosis of Alzheimer's disease
according to NINCDS/ADRDA.
Watson 2019 included 75 subjects with a ‘cognitive level of moderate or higher’
defined by an MMSE score >10. Included in this review were the 56 (75%) of the
participants had a clinical diagnosis of dementia.
Yang 2015 included 186 participants who were diagnosed with dementia according
to DSM-IV criteria and scored 35 or above on the CMAI, 130 participants were
randomised to the two groups included in this review.
Yang 2016 included 59 people with mild to severe dementia who displayed
symptoms of agitation or depression in the two weeks prior to the study. The
diagnosis of dementia was based on the Short Portable Mental Status Question
(SPMSQ) (scoring ≤8) or the Mini-Mental State Examination (MMSE) (scoring ≤17 if
the participant had a high school education or ≤23 if the participant had a high school
education or higher (sic)). Agitation and depressive symptoms were reported by
caregivers using the Chinese version of the CMAI (long version) and CSDD-C; cut-
offs for inclusion were not reported.
4. Interventions
Lavender was the most commonly used fragrance, administered in nine studies. In
one study (Yang 2016), lavender oil was combined with orange oil. One study
(Watson 2019) included both lavender and lemon balm aromatherapy groups. Three
studies (Ballard 2002, Burns 2011, Cameron 2011) used lemon balm aromatherapy
only. One study (Takahashi 2020) used aroma from cedar extracts. Six studies
administered aromatherapy using touch or massage (Ballard 2002, Burns 2011,
Cameron 2011, Hanson 2013, O'Connor 2013, Yang 2016). Four studies
administered aromatherapy by exposure to fragrance only (Fujii 2008, Lin 2007,
Takahashi 2020, Watson 2019). Two studies used more than one application
technique. In one of these studies (Fu 2013), aromatherapy was administered via a
mist and accompanied with a hand massage, or just administered via the mist.
Smallwood 2001 applied aromatherapy either through massage or via a diffuser,
which was accompanied with conversation. One study (Yang 2015) administered
aromatherapy by applying aromatherapy oil to acupressure points without any
pressure.
Ballard 2002 used 10% lemon balm and base oil applied topically to the arms and
face for one to two minutes. The control condition was sunflower oil applied in the
same way. The oil was applied twice daily for four weeks.
Burns 2011 used 10% lemon balm oil which was gently massaged on the hands and
upper arms for one to two minutes. The control condition was sunflower oil applied in
the same way. The oil was applied twice daily for twelve weeks. Both the
aromatherapy and placebo aromatherapy groups received placebo medication. The
study also included a third group which involved placebo aromatherapy and
Donepezil medication, however, we are not including this group in this review.
Cameron 2011 used < 2% lemon balm oil aromatherapy which was applied by gently
rubbing the patients forearm for one minute twice a day. The control condition was
1% geranium and 0.5% lemon oil applied in the same way. There were two treatment
phases of three weeks and a one-week washout period between phases, the trial
was repeated after one year.
Fu 2013 had two aromatherapy intervention groups, both used 3% lavender mist
aromatherapy, one group with and another without hand massage. Three sprays of
the lavender mist was applied to the participants' upper chest. The control condition
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was water mist applied in the same way. The interventions were given twice a day for
six weeks.
Fujii 2008 used lavender oil as the aromatherapy intervention. Two drops of lavender
oil was applied to the collar of the patients underwear, approximately one hour after
meals, three times a day for four weeks. The control group did not receive any active
treatment.
Hanson 2013 used lavender oil applied to the spine, back and neck at bedtime,
followed by a 20 minute diffuser containing lavender oil. The control condition was
almond oil administered in the same way. During acclimation (week one), while
dressing for participant’s bedtime, resident assistants applied lotion. Participants
then received either lavender or placebo (almond) oil in week two, and switched to
the other oil during week 3. A diffuser containing the corresponding treatment was
also turned on for 20 minutes.
Lin 2007 used 100% lavender essential oil which was dropped onto cosmetic cotton
and placed into two diffusers at each side of the participant's pillow. The diffusers
were used for at least one hour whilst the participants slept at night. The control
condition was sunflower oil administered in the same way. One of the interventions
was administered for the first three weeks of the study, followed by a two week
washout period, then the second intervention was administered for three weeks.
O'Connor 2013 used 30% lavender in jojoba oil which was massaged into both
forearms for one minute each. The control condition was jojoba oil administered in
the same way. The intervention was administered three times during the first week of
the study when nursing staff reported that agitated behaviour was likely to be
displayed. There was a four day washout period followed by the second intervention
being administered three times in the last week of the study.
Smallwood 2001 used two aromatherapy groups: lavender applied topically through
massage and lavender in a diffuser accompanied by conversation. The control
condition was massage only using plain oil. The interventions were administered
twice a week for four weeks.
Takahashi 2020 used cedar extracts in a distilled ethanol solution. Each day, 2.3mL
of the distilled solution with cedar extracts was placed in the residents living room
and bedroom and the solution was diffused using rattan sticks. A few times a day,
the distilled solution with cedar was also sprayed as a mist on the patients' clothing
and bedding. The control condition was the distilled ethanol solution without the
cedar extracts, administered in the same way. The interventions were performed for
eight weeks.
Watson 2019 used three interventions; lavender, lemon balm and a placebo. Two
drops of oils were applied to a cotton patch and attached to the participants collar for
two hours for 14 consecutive days. This was followed by a washout period before
commencing the next intervention.
Yang 2015 used 2.5% lavender oil which was applied at five acupoints which was
followed by a warm up exercise carried out for five minutes. The duration of each
protocol was no longer than 15 minutes, and each protocol was conducted once per
day for five days per week for four weeks total. The control condition was normal
daily care routine continued as usual without interventions. The study also included a
third group, the aroma-acupressure group (five acupoints were pressed for two
minutes with 2.5% lavender oil followed by a warm up exercise carried out for five
minutes), but we are not including this group in this review.
Yang 2016 used Lavender and orange oil three drops of each in 5ml of “essential oil”
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applied topically around neck, shoulders and arms 30 minutes once per week for
eight weeks (weeks two-nine of study) as their intervention. The control condition
was usual care with participation in regular activities (e.g. group singing, watching
movies) in the long-term care facilities.
5. Outcomes
Most trials applied validated outcome scales at baseline and at the end of the
intervention period, or – in the case of the crossover trials – at the beginning and end
of each treatment period. Less than half of the trials assessed outcomes at
intermediate time points, but we did not include these data. Two trials (O'Connor
2013 and Smallwood 2001) used intensive observation to collect outcome data
before and after each treatment application and synthesised these data to provide an
outcome score. Similarly, Hanson 2013, which was the only trial to assess sleep,
used actigraph data collected throughout the whole intervention period to derive their
sleep outcome. Only two trials (Fu 2013 and Yang 2015) looked for persistent effects
by re-assessing outcomes six and three weeks respectively after the end of the
intervention period.
Outcome assessment tools -
1. Agitation
i) Cohen-Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield 1999): in Ballard
2002; Cameron 2011; Watson 2019; Fu 2013, which used the short version; and Lin
2007, Yang 2015 and Yang 2016, which used the Chinese version of this scale. This
is a seven-point rating scale that assesses the frequency of agitated behaviour. A
higher score indicates more agitation.
ii) Pittsburgh Agitation Scale (PAS) (Rosen 1994): in Burns 2011 and Cameron 2011.
This scale measures agitation using four behaviour groups of aberrant vocalisation,
motor agitation, aggressiveness, and resisting care. A higher score indicates more
agitation.
iii) O'Connor 2013 measured agitation by recording whether the behaviour was
absent or present over three 30-minute observation periods.
iv) Smallwood 2001 used video records to assess agitated behaviour at baseline and
immediately after treatment. Smallwood 2001 used a video camera to record
behaviour for 15-minute periods over a day in a specified sequence and frequency.
The video records were sampled and coded into six behaviour categories developed
by two blinded raters.
2. Overall behavioural and psychological symptoms
i) Neuropsychiatric Inventory (NPI) (Cummings 1994): in Ballard 2002; Burns 2011;
Cameron 2011; Fujii 2008; Hanson 2013; Takahashi 2020; Watson 2019; and Lin
2007, using the Chinese version of this scale. This scale assesses either 10 or 12
behavioural disturbances common in dementia: delusions, hallucinations, dysphoria,
anxiety, agitation or aggression, euphoria, disinhibition, irritability or lability, apathy,
and aberrant motor activity. A higher score indicates greater severity of these
behaviours.
3. Adverse effects
i) Adverse effects were measured in Burns 2011; Cameron 2011; Fu 2013 and
O'Connor 2013.
4. Quality of life
i) Blau Quality of Life (Blau 1977) - in Burns 2011. This scale measures subjective
quality of life in a mental health setting using 10 items. A higher score indicates
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better quality of life.
ii) Dementia Care Mapping (Kitwood 1992) - in Ballard 2002. Dementia Care
Mapping is an observational method to evaluate quality of care and life in people with
dementia.
5. Mood
i) Cornell Scale for Depression in Dementia-Chinese Version (CSDD-C) (Lin 2008) in
Yang 2016, using the Chinese version of this scale. This scale uses a
comprehensive interviewing approach that derives information from the patient and
the informant. The interviews focus on depressive symptoms and signs occurring
during the week preceding the interview. The final ratings of the CSDD items
represent the rater's clinical impression rather than the responses of the informant or
the patient.
ii) Philadelphia Geriatric Center Affect Rating Scale (PGCARS) (Lawton 1996): in
O'Connor 2013. This scale assesses affect including: pleasure, anger, sadness,
contentment, interest and anxiety/fear.
6. Sleep
i) Hanson 2013 assessed sleep by measuring time spent sleeping across four
epochs of actigraph data and a sleep log completed by staff.
7. Cognition
i) Mini Mental State Examination (MMSE) (Folstein 1975): in Fu 2013 and Fujii 2008.
This scale measures cognitive impairment. A higher score indicates less cognitive
impairment.
ii) Alzheimer's Disease Assessment Scale-cognitive subscale (ASDAS-cog) (Rosen
1984): in Takahashi 2020. This scale measures cognitive dysfunction in Alzheimer's
disease.
8. Activities of daily living
i) Barthel scale of Activities of Daily Living (Mahoney 1965): in Burns 2011 and Fujii
2008. This scale measures performance in activities of daily living. A higher score
indicates better functioning.
9. Caregiver burden or distress, or both
i) Japanese version of the Zarit Caregiver Burden interview (J-ZBI) (Arai 1997): in
Takahashi 2020. This tool measures caregiver burden.
6. Additional data obtained from study authors
For the previous version of this review (Forrester 2014), Professor Ballard provided
access to the individual patient data from his cluster-randomised study (Ballard
2002). Reviewers performed analyses additional to those that had been published
using the PROC MIXED procedure in SAS® 1999. The nursing homes were the
units of randomisation. For each outcome, the mean change from baseline of all
residents within a home was the outcome value for the home. The treatment effect
for an outcome was the difference between the overall means of the four homes on
treatment and the four homes on placebo (Table 1). The contribution from each
home was weighted and this weight depended on the precision of the mean value for
each home. Analysis of co-variance was used for all outcomes, with the nursing
home being treated as a random effect. There were several participant level
covariates that could be included in the model, such as age, sex, baseline outcomes,
and the medication being taken (Table 2). When tested in the model for each
outcome, the only medication variable that had a significant effect was whether the
patient was taking atypical antipsychotics. Sex and the baseline value of the
outcome measure also had significant effects. Therefore, the estimate of the
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treatment effect was adjusted for sex, baseline measure of the outcome, and use of
atypical antipsychotic medication.
Excluded studies
Forty-three studies were excluded: two were systematic reviews and one was a
literature review; two studies were in vitro studies and one was an animal study;
twenty-one were not randomised; two did not have a control condition; nine studies
did not have aromatherapy as the intervention; and in five studies the participants did
not have dementia.
Ongoing studies
There were two ongoing studies ACTRN12617001159347 and ChiCTR-INR-
17013281. Our attempts to contact the authors for further information were
unsuccessful. See Ongoing studies for details.
Risk of bias in included studies
See also Characteristics of included studies, Figure 2, and Figure 3.
Allocation
We considered six studies to be at low risk of bias for sequence generation and
seven studies to be at unclear risk. For allocation concealment, we considered the
risk of bias to be low in six trials and unclear in all remaining trials.
Blinding
Seven trials had a low risk of bias for blinding of participants and personnel, four
were unclear, and two trial was high risk. 10 were low risk for blinding of outcome
assessors, two trials were unclear, and one trial was high risk. Authors went to
considerable lengths to try to blind personnel, including use of nose pegs and
masking oils applied to the upper lip of personnel administering the treatments.
Active and placebo oils were identified by letters and provided in identical containers.
In some studies, personnel were not informed of the study hypothesis. We did not
consider lack of blinding of participants to present a major risk of bias because of
their degree of cognitive impairment.
Incomplete outcome data
We considered the risk of bias due to incomplete outcome data to be low in nine
trials, unclear in two trials (Cameron 2011; Takahashi 2020) due to lack of
information and high in two trials (Hanson 2013 where outcome data were reported
for only 50% of participants; Watson 2019 where there was no reporting of attrition
by group).
Selective reporting
Three studies had a high risk of bias for selective reporting, the other studies had a
low risk of bias.
Other potential sources of bias
Yang 2015 was rated as unclear bias because there was possible recruitment bias
before or after cluster allocation. There was also possible analysis bias as the study
does not specify whether clustering was taken account in the statistical analysis. We
rated Hanson 2013 as high risk of bias as limited information about the methods was
presented on the conference poster and abstract. The remaining studies were rated
as low risk of bias.
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Effects of interventions
The diversity of the data and inadequate reporting in many studies meant that no
pooling of data was possible. We present here the results from each included study.
For each study, we also make an assessment of our confidence in the result, taking
into account concerns about risk of bias, analysis method, imprecision and
indirectness.
Unless otherwise stated, all the results reported are from the end-of-treatment time
points.




Ten studies measured the effects of aromatherapy on agitated behaviour.
Ballard 2002 (71 participants) applied lemon balm essential oil or placebo oil twice
daily for four weeks. Agitation was assessed using the CMAI. The authors of a
previous version of this review conducted analyses on individual patient data
provided by the study authors (see point 6 in Included studies above). The analysis
was adjusted for clustering and for several participant-level covariates. The mean
difference between aromatherapy and placebo groups in change from baseline in the
mean total CMAI score after four weeks of treatment was -11.1 favouring the
aromatherapy group (95% CI -20.0 to -2.2; one study, 71 participants). The study
was at low risk of bias in all domains and we were moderately confident in this result
(downgraded one level due to imprecision because of the small sample size).
Burns 2011 (63 participants) applied lemon balm essential oil or placebo oil twice
daily for twelve weeks. Agitation was assessed using the PAS at baseline and after
four and 12 weeks of treatment. PAS data were reported as medians because of a
non-normal distribution and treatment groups were compared using a Kruskal-Wallis
test. The authors reported no significant difference between placebo and
aromatherapy groups on the PAS at week four or week 12. The study was at low risk
of bias in all domains and we were moderately confident in this result (downgraded
one level due to imprecision).
Cameron 2011 (18 participants) applied lemon balm oil or placebo oil twice a day for
three weeks. This was a crossover study. Agitation was assessed using the PAS and
CMAI. No numerical data were reported. The authors reported no significant
difference between treatment groups, but no details were given of the analysis
method. We had very low confidence in this result due to lack of information on
participant attrition, outcome data and analysis methods, and the very small sample
size.
Fu 2013 (61 participants) applied 3% lavender mist aromatherapy twice a day for six
weeks. Water mist was used in the control condition. Agitation was assessed using
the CMAI-SF. They did not report any numerical data for total CMAI-SF scores, nor
any analysis of between-group differences.
Lin 2007 (70 participants) administered lavender essential oil or a placebo oil in a
diffuser for one hour per night for three weeks. Agitation was assessed using the
Chinese version of the CMAI (CCMAI). This was a crossover study. Mean (SD)
scores on the CCMAI were reported for aromatherapy and placebo groups at
baseline and after three weeks of treatment. Paired data were not reported. First-
period-only data were not reported. We used the final scores reported for each
treatment group to calculate a mean difference between aromatherapy and placebo
groups after three weeks of treatment. Negative scores favour the aromatherapy
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group. The MD was -5.13 (95% CI -13.21 to 2.95; one study, 70 participants). We
had low confidence in this result due to serious concerns about risk of bias
(especially lack of blinding of outcome assessment), our inability to conduct or report
a paired analysis suitable to the crossover design, and imprecision.
O'Connor 2013 (64 participants) administered lavender essential oil or control oil
three times over the course of one week. Physically agitated behaviours were
measured by observing and counting target behaviours for 30 minutes before the
intervention and 60 minutes after the intervention and then calculating a mean
behaviour count for each of one 30-minute pre-exposure period and two 30-minute
post-exposure periods. This was a crossover study. Paired data were not reported.
First-phase-only data were not reported. Data were analysed using binomial
regression. The study reports that behaviour counts reduced significantly following
both aromatherapy and placebo interventions, but that there was no statistically
significant treatment effect (no significant treatment x time interaction). The risk of
bias was low in all domains. Our confidence in the study was moderate, reduced due
to imprecision.
Smallwood 2001 (21 participants) administered lavender oil or a control oil either via
a diffuser or via massage, twice a week for four weeks. Agitation was assessed by
measuring motor behaviour from 15-minute video recordings of participants. No
numerical data were reported. The authors compared the two aromatherapy
conditions and the placebo group using a one-way ANOVA and reported no
significant between-group differences (p>0.1 for all comparisons). We had very low
confidence is this result due to imprecision, indirectness (motor behaviour as a proxy
for agitated behaviour), lack of data presented in the paper, and risk of bias.
Watson 2019 (39 participants) administered lavender, lemon balm or placebo oil
once a day for two weeks. Agitation was assessed using the CMAI, but the study did
not report any data on CMAI scores in the separate treatment groups and did not
report any relevant analysis of between-group differences.
Yang 2015 (130 participants) administered lavender oil once per day, five days a
week for four weeks. The comparator was no intervention. Agitation was assessed
using the CCMAI. This was a cluster-randomised trial. There was no indication that
analyses were adjusted for clustering. The authors reported that the CMAI score was
significantly higher in the aromatherapy group than the control (no intervention)
group before treatment. From the data given, there was no change between baseline
and end-of-treatment in the CMAI score in the aromatherapy group; the CMAI score
in the control group increased over the treatment period to a score very similar to
that in the aromatherapy group, suggesting that the authors’ conclusion of a positive
effect of aromatherapy may have been attributable largely to the baseline imbalance.
Our confidence in the results of this study was very low due to serious concerns
about risk of bias, incorrect analysis and imprecision.
Yang 2016 (56 participants) administered lavender and orange oil once per week for
eight weeks. The comparator was no intervention. Agitation was assessed using
modified scoring of the 24-hour CCMAI (no information on validation given).
Measurements were made at baseline, and 24 hours after massage halfway through
the 8-week intervention and at the end of the intervention period. The authors used a
general linear model repeated measurement analysis and report that “no significant
difference was noted between groups regarding overall agitation” (P=0.316). Our
confidence in this result was low due to serious concerns about risk of bias and
imprecision.
In summary, although agitation was an outcome in ten trials, two of them provided no
relevant data or analyses and our confidence in the results of three more was very
low. We had low confidence in the results of two trials, in both of which aromatherapy
had no significant effect on agitation. We were moderately confident in the results of
the three remaining trials, which were of a similar size and used similar interventions.
One of these trials found a statistically significant effect of aromatherapy on agitation
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while the other two did not. The balance of the evidence is against a positive effect of
aromatherapy on agitation, but inconsistency, serious study limitations, imprecise
results and publication bias make this a tentative conclusion.
2. Overall behavioural and psychological symptoms
Eight studies measured the effects of aromatherapy on behavioural and
psychological symptoms.
Ballard 2002 (71 participants) assessed overall behavioural and psychological
symptoms using the NPI. The authors of a previous version of this review conducted
analyses on individual patient data provided by the study authors (see point 6 in
Included studies above). The analysis was adjusted for clustering and for several
participant-level covariates. The mean difference between aromatherapy and
placebo groups in change from baseline in the mean total NPI score after four weeks
of treatment was -15.8, favouring the aromatherapy group (95% CI -24.4 to -7.2; one
study, 71 participants). The study was at low risk of bias in all domains and we were
moderately confident in this result (downgraded one level due to imprecision
because of the small sample size).
Burns 2011 (63 participants) assessed overall behavioural and psychological
symptoms using the NPI and found no significant difference in behavioural
symptoms between those treated with aromatherapy and those treated with placebo
after 12 weeks (n = 63, MD 2.80, 95% CI -5.84 to 11.44). The study was at low risk of
bias in all domains and we were moderately confident in this result (downgraded one
level due to imprecision).
Cameron 2011 (18 participants) assessed overall behavioural and psychological
symptoms using the NPI. This study was a crossover study. No numerical data were
presented. The authors report no significant difference between treatment groups,
but no details were given of the analysis method. We had very low confidence in this
result due to lack of information on participant attrition, outcome data and analysis
methods, and the very small sample size.
Fujii 2008 (28 participants) administered lavender oil three times a day for four
weeks. The comparator was no intervention. Overall behavioural and psychological
symptoms were assessed using the NPI. We used the final scores reported for each
treatment group to calculate a mean difference between aromatherapy and placebo
groups at 4 weeks. The mean difference was -9.0 favouring the aromatherapy group
(95% CI -17.89 to -0.11; one study, 28 participants). We had low confidence in this
result due to imprecision and risk of bias.
Hanson 2013 (21 participants) administered lavender oil or placebo oil via touch and
via a diffuser. Overall behavioural and psychological symptoms were assessed using
the NPI, but the study reported no useable data. This was a crossover study.
Lin 2007(70 participants) assessed overall behavioural and psychological symptoms
using the NPI. This was a crossover study. Paired data were not reported. First
period only data were not reported. We used the final scores reported for each
treatment group to calculate a mean difference between aromatherapy and placebo
groups after three weeks of treatment. Negative scores favour the aromatherapy
group. The MD was -6.64 (95% CI -10.85 to -2.43; one study, 70 participants). We
had low confidence in this result due to serious concerns about risk of bias
(especially lack of blinding of outcome assessment), our inability to conduct or report
a paired analysis suitable to the crossover design, and imprecision.
Takahashi 2020 (36 participants) used a distilled cedar and ethanol solution diffused
as a room fragrance as well as a mist spray, sprayed on patients clothes a few times
a day. Takahashi 2020 assessed overall behavioural and psychological symptoms
using the NPI and report that the NPI score of the aromatherapy group significantly
decreased in comparison to the control group. We used the final scores reported for
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each group to calculate a mean difference between aromatherapy and placebo
groups at eight weeks. The mean difference was -4.26 favouring the aromatherapy
group (95% CI -9.46 to 0.94; one study, 36 participants). We had low confidence in
this result due to imprecision and concerns about risk of bias.
Watson 2019 (39 participants) assessed overall behavioural and psychological
symptoms using the NPI but did not report any data on NPI scores in the separate
treatment groups and did not report any relevant analysis of between-group
differences.
In summary, eight studies assessed overall behavioural and psychological symptoms
using the total NPI score. Two studies provided no useable data and we have very
low confidence in the result of one more study. We had low confidence in the results
of three trials, all of which showed a reduction in overall behavioural and
psychological symptoms following aromatherapy. We were moderately confident in
the results of the two remaining trials, which were of a similar size and used similar
interventions. One of these trials found a statistically significant effect of
aromatherapy on overall behavioural and psychological symptoms; the other did not.
3. Adverse Effects
Four studies mentioned adverse events occurring during the trial.
Burns 2011 (63 participants) reported that two participants in the aromatherapy
group and two participants in the control group suffered serious adverse events. The
authors also report 27 adverse events but do not specify which treatment group
suffered the adverse events. The study was at low risk of bias in all domains and we
were moderately confident in this result (downgraded one level due to imprecision
because of the small sample size).
Cameron 2011 (18 participants) reported three deaths but stated these deaths were
not as a result of the aromatherapy treatment. There was no information on
systematic assessment of adverse events.
Fu 2013 (61 participants) reported that there were no adverse events in the control
group or treatment group.
O'Connor 2013 (64 participants) reported that there were no adverse events in the
control group or treatment group.
In summary, adverse events were poorly reported or not reported at all in most trials.
What data there were did not raise concern about adverse effects of aromatherapy in
this patient population.
Secondary outcomes
1. Quality of life
One study (Burns 2011) assessed the effect of aromatherapy on a quality of life
scale. Ballard 2002 included Dementia Care Mapping (DCM) and reported the effect
of aromatherapy on the percentage of time participants spent socially withdrawn or
participating in constructive activities. We decided to report this here under the QoL
outcome, but to consider it an indirect measure of QoL.
Ballard 2002 (71 participants) reported DCM data as medians. Compared to the
control group, the aromatherapy group spent a significantly lower percentage of time
socially withdrawn (p = 0.05) and a significantly higher percentage of time engaged
in constructive activities (p = 0.01). The study was at low risk of bias in all domains,
but we considered it indirect in relation to quality of life. Hence our confidence in this
as a QoL result was low (downgraded due to imprecision because of the small
sample size and due to indirectness).
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Burns 2011 (63 participants) assessed QoL using the Blau QOL Scale at baseline
and after four and 12 weeks of treatment. The authors reported no significant
difference between placebo and aromatherapy groups on the Blau QOL Scale at
week 4 or at week 12 (MD = 19.00, 95% CI -23.12 to 61.12, one study, 63
participants). The study was at low risk of bias in all domains and we were
moderately confident in this result (downgraded one level due to imprecision).
In summary, two trials assessed quality of life, or aspects of QoL, using different
assessment tools. We were moderately confident in one trial which did not find any
significant effect of aromatherapy on QoL. Because of the indirectness of the
measure used in the other study, we had low confidence that the beneficial effect of
aromatherapy in this trial reflected an effect on overall QoL.
2. Mood
Two studies measured the effect of aromatherapy on mood.
O'Connor 2013 (64 participants) assessed mood using the PGCARS, recording the
main type of affect displayed every minute for 30 minutes before the intervention and
60 minutes after the intervention, and then calculating mean scores for positive and
negative affects for each of one 30-minute pre-exposure period and two 30-minute
post-exposure periods. This was a crossover study. Paired data were not reported.
First-phase-only data were not reported. Data were analysed using binomial
regression. The study reports no effect of treatment on positive or negative affects
(no treatment x time interactions). The risk of bias was low in all domains. Our
confidence in the study was moderate, reduced due to imprecision (small sample
size).
Yang 2016 (56 participants) assessed mood by using the CSDD-C. Measurements
were made at baseline, and 24 hours after massage halfway through the 8-week
intervention and at the end of the intervention period. There appears to be a baseline
imbalance with higher depressive symptom scores in the aromatherapy group at
baseline. The authors used a general linear model repeated measurement analysis
and report that “Depressive symptoms decreased significantly over time for the
intervention group compared to the control group” (P<0.001). Our confidence in this
result was low due to serious concerns about risk of bias and imprecision (small
sample size).
In summary, mood or affect was an outcome in two trials. We were moderately
confident in the results of one trial which found no significant effect of aromatherapy
on affect. Another trial did report a statistically significant benefit or aromatherapy on
depressive symptoms, but we had low confidence in this result.
3. Sleep
One study measured the effect of aromatherapy on sleep.
Hanson 2013 (21 participants) assessed sleep but reported no useable data. This
was a crossover study.
4. Cognition
Three studies measured the effect of aromatherapy on cognition.
Fu 2013 (61 participants) stated that they assessed cognition using the MMSE at
baseline and at the end of the trial but did not report this outcome.
Fujii 2008 (28 participants) assessed cognition using the MMSE. We used the final
scores reported for each treatment group to calculate a mean difference between
aromatherapy and placebo groups at four weeks. The mean difference was 1 MMSE
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point (95% CI -4.19 to 6.19; one study, 28 participants). We had low confidence in
this result due to concerns about risk of bias and imprecision.
Takahashi 2020 (36 participants) assessed cognition using ADAS-cog and reported
no difference between the aromatherapy and control groups. We used the final
scores reported for each treatment group to calculate a mean difference between
aromatherapy and placebo groups at eight weeks. The mean difference was -0.36
(95% CI -6.60 to 5.88; one study, 36 participants). We had low confidence in this
result due to concerns about risk of bias and imprecision.
In summary, three trials apparently assessed cognitive outcomes. One did not report
any data. The two other trials found no significant effect of aromatherapy on
cognition; our confidence in the results of these studies was low.
5. Activities of daily living
Two studies measured the effect of aromatherapy on activities of daily living.
Burns 2011 (63 participants) assessed activities of daily living using the Barthel Index
for Activities of Daily Living. They found no significant difference in activities of daily
living between those treated with aromatherapy and those treated with placebo after
12 weeks, mean difference -0.50 (95% CI -1.79 to 0.79; one study, 63 participants).
The study was at low risk of bias in all domains and we were moderately confident in
this result (downgraded one level due to imprecision).
Fujii 2008 (28 participants) assessed activities of daily living using the Barthel Index
for Activities of Daily Living. The study measured this but did not include quantitative
data and did not conduct between group analysis.
In summary, two trials assessed activities of daily living. One did not report any
useable data. The other found no significant effect of aromatherapy on activities of
daily living; we were moderately confident in this result.
6. Caregiver burden or distress, or both
One study measured the effect of aromatherapy on caregiver burden.
Takahashi 2020 (36 participants) assessed caregiver burden using the Japanese
version of the Zarit Caregiver Burden interview. The study reported that the caregiver
burden score was significantly lower in the aromatherapy group than in the placebo
group. We used the final scores reported for each treatment group to calculate a
mean difference between aromatherapy and placebo groups at eight weeks. The
mean difference was -6.27 (95% CI -12.29 to -0.25; one study, 36 participants). We
had low confidence in this result due to concerns about risk of bias and imprecision.
Discussion
Summary of main results
See Summary of findings table 1
For all efficacy outcomes there was inconsistency between trials largely because one
study (Ballard 2002) reported beneficial effects of aromatherapy. We had varying
levels of confidence in the trials. We found no convincing benefit of aromatherapy on
agitation and overall behavioural and psychological symptoms. Reporting of harms
was very poor with only four trials making any mention of adverse events. Two trials
assessed quality of life and reported inconsistent results. Two trials assessed mood
and reported inconsistent results. One study in our review assessed sleep but
reported no useable data. Cognition was reported in three trials: two trials reported
no significant effect of aromatherapy on cognition, the other trial reported no useable
data. Activities of daily living was reported in two trials: one did not report any
useable data, the other trial found no significant effect of aromatherapy on activities
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of daily living. One study measured caregiver burden and reported a reduction
following the aromatherapy intervention.
Overall completeness and applicability of evidence
All of the participants in the trials had dementia and were recruited from care facilities
or hospital wards (one trial did not specify where the participants were recruited
from), therefore findings from these trials cannot be applied to community settings.
As discussed above, the range of reported outcomes was limited and there was very
little systematic reporting of adverse events. Aromatherapy involves the exposure to
plant-based aromas. One study used cedar extracts, the remaining twelve studies
used essential oils. Complementary medicine practitioners may consider this to be
exposure to essential oil fragrances rather than aromatherapy.
Quality of the evidence
A meta-analysis could not be performed as the trials were heterogeneous and many
did not report any useable numerical data. We reported numerical data from
individual studies where possible, but were only able to compare results of studies
using a p value ≤ or > 0.5 in our narrative synthesis, which we recognise is a poor
metric.
We used GRADE to assess the quality of the evidence for each outcome; this
ranged from very low to moderate. The major problem was imprecision due to small
sample sizes. Among higher quality studies there was inconsistency in their results.
Key methodological issues include the quality of the blinding, the placebo effect, poor
reporting of the concentration of constituents in the aromatherapy substances used,
and the comparability of different interventions. Many of the aromatherapy
interventions involve an increase in interaction with other people which could help to
relieve the symptoms of dementia, irrespective of the aromatherapy treatment. Three
of the included studies compared an aromatherapy intervention to usual care and
therefore do not control for an increase in attention from others. No studies assessed
whether the aromatherapy substances were present systemically, providing no
insight into the pharmacokinetics of aromatherapy.
Potential biases in the review process
We are unable to exclude publication bias.
Agreements and disagreements with other studies
or reviews
Kim 2019 is a systematic review of the effect of aromatherapy on agitation in people
with dementia. Kim 2019 reported that aromatherapy is beneficial at improving
agitation in individuals with dementia. The review included 12 aromatherapy trials,
eight of these trials are included in the current review (Ballard 2002, Burns 2011, Fu
2013, Lin 2007, O'Connor 2013, Yang 2015, two studies were referenced in relation
to Yang 2016). The four other trials (Akhondzadeh 2003, Holmes 2002, Snow 2004,
Yoshiyama 2015) were not included in the current review because Akhondzadeh
2003 administered aromatherapy orally, Holmes 2002 and Snow 2004 were not
randomised controlled trials, and Yoshiyama 2015 is currently awaiting classification,
the author has been contacted as no useable data were presented in this small pilot
study.
Leng 2019 is a systematic review on the use of non-pharmacological interventions
for agitation in people with dementia. Leng 2019 reported that aromatherapy did not
have a beneficial effect on agitation in individuals with dementia. The review included
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six aromatherapy trials, four of these trials are included in the current review (Burns
2011, Lin 2007, Yang 2015 and Yang 2016), the other two trials (Dimitriou 2018 and
Kaymaz 2017) were not included in the current review because Kaymaz 2017 was
not a randomised controlled trial and Dimitriou 2018 did not include a control group.
Oliveira 2015 is a systematic review on the use of non-pharmacological interventions
to reduce behavioural and psychological symptoms of dementia. Oliveira 2015
reports that aromatherapy may be beneficial at reducing agitation in patients with
dementia. The review includes only three aromatherapy trials (Burns 2011, Lin 2007
and Yang 2015), all of these trials are included in the current review.
Livingston 2014 is a systematic review on the use of non-pharmacological
interventions for agitation in dementia in randomised control trials. Livingston 2014
reports that aromatherapy appears to be effective when the intervention is non-
blinded, but when raters are blinded, aromatherapy does not appear to be effective
in reducing agitation. The review includes only two aromatherapy trials (Ballard 2002
and Burns 2011), both of which are included in the current review.
Fung 2012 is a systematic review on the use of aromatherapy in treating behavioural
problems in dementia. Fung 2012 reports that there is some evidence that
aromatherapy has a positive effect on cognitive functioning and reducing BPSDs.
However, although the review stated that they included only RCTs, six of the 11
included studies were not randomised and one was not testing aromatherapy, and so




The use of aromatherapy for people with dementia in long-term care facilities and hospital
wards is feasible. From the available evidence, it is not possible to be certain whether or not
patients with dementia and agitation or other signs of distress will benefit from
aromatherapy. Reporting of adverse events in the trials was very poor. Although the four
trials which mentioned them did not detect adverse effects, it is not possible to assume that
aromatherapy is without risk of harm.
Implications for research
A promising start has been made in systematically investigating the effect of aromatherapy
for dementia, however well-designed, larger RCTs that fully report the data are needed
before conclusions can be drawn as to its effectiveness. Many methodological issues need
to be addressed such as the quality of the blinding, the comparability of different
interventions, and the placebo effect. Control conditions should account for any increase in
social interaction that occurs during the aromatherapy intervention. Treatment effects at
different severities of dementia should be investigated. Future research should involve
pragmatic randomised controlled trials of the most widely used aromatherapy fragrances,
using patient-important outcome measures, preferably from a well-derived core outcome set
and assessing systematically for any harms. The concentration of constituents in the
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Outcome or subgroup title No. of studies No. ofparticipants
Statistical
method Effect size
i l i i i
i i l i
1.1 Agitation, mean change
(CMAI, high score=bad) 1
Other
data No numeric data
1.2 Behavioural symptoms,
mean change (NPI, high
score=bad)





New citation required but
conclusions have not changed
Six new studies were included and the content revised
and updated. Conclusions unchanged
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An update search was performed for this review on 17 May 2010. The








An update search was run in March 2008 that retrieved one study (Lin 2007)
which has been included in the review. No data from this trial has been
included as data from the first phase of this crossover trial was not reported
in the study report and has not been forthcoming from the study author.
This update has been conducted by Theo Birks and Francesca Holt and








2008 Amended Converted to new review format.









Four new papers were identified in the search of April 2006. Three were of
new trials, two were excluded and one is ongoing (Myers 2005). The fourth
paper is a commentary on an existing included trial (Lee 2003 b attached to
Smallwood 2001). This update was performed by the CDCIG editorial base
and approved by Martin Orrell and the Contact Editor as the first author
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Differences between protocol and
review
The methods section has been updated to the current methods in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011), the previous
version of the methods can be found in Appendix 4.
Primary outcome Behavioural symptoms changed to Overall behavioural and
psychological symptoms
Added that all outcomes had to be measured using validated scales.
Added that where studies used a crossover method, we used the final scores
reported for each treatment group to calculate a mean difference between
aromatherapy and control groups following the intervention.
Characteristics of studies





Treatment allocation: cluster-randomised controlled trial
Study design: parallel group
Intervention: four weeks
Assessments: conducted at baseline and following the four week intervention
Participants Country: UK
Participants recruited from: eight specialist nursing homes
Number of participants randomised: 72 participants
Number of participants included in analysis: 71 participants
Mean age of participants: The mean age of participants who were randomised
was 78.5 years, SD = 8.1 (active treatment = 77.2 years; placebo = 79.6 years)
Sex of participants: The percentage of females who were randomised was 60%
females (active treatment = 56% female; placebo = 64% female)
Inclusion criteria:
1. Occupants of nursing homes were people with severe dementia (CDR=3) and
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clinically significant agitation (defined as occurring on a daily basis and causing
moderate to severe management problems)





Intervention groups included in this review:
1. 10% lemon balm essential oil and base oil (200mg/day divided into two doses),
applied topically to the face and both arms twice a day by a care assistant. N=36
allocated to this intervention.
2. 10% sunflower oil and base oil (200mg/day divided into two doses), applied
topically to the face and both arms twice a day by a care assistant. N=36
allocated to this intervention.
Outcomes
Outcomes included in this review:
1. Agitation: CMAI
2. Behavioural symptoms: NPI
3. Quality of life: Dementia Care Mapping (% of time spent socially withdrawn, %
of time engaged in constructive activities)
Notes
Risk of bias






"The facilities were matched in pairs (according to number of
residents) and then assigned randomly (using the toss of a coin), to





"The facilities were matched in pairs (according to number of
residents) and then assigned randomly (using the toss of a coin), to








"In each facility only one of the aromatherapy substances was used,
preventing comparisons between agents by staff. For the same
reason staff were not informed of the nature of either the active












"Seventy-one (99%) participants completed the 4 week trial, one
participant receiving active treatment died over the course of the
study (unrelated to the study treatment)"
Selective reporting
(reporting bias) Low risk All outcomes reported
Other bias Low risk
The published data were not adjusted for clustering, however,
unpublished individual patient data were provided and we adjusted




Treatment allocation: randomised controlled trial
Study design: parallel group
Intervention: 12 weeks
Assessments: conducted at baseline, week four and week 12
Participants Country: UK
Participants recruited from: three clinical centres (Manchester, London and
Southampton)
Number of participants randomised: 114 participants, of whom 77 were
randomised to the two groups included in this review
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Number of participants included in analysis: 63 participants (week four), 55
(week 12)
Mean age of participants: The mean age of participants who completed the
week four assessment was (active treatment = 85.6 years; placebo = 85.1 years).
The mean age of participants who completed the week 12 assessment was not
provided.
Sex of participants: The sex of participants who completed the week four
assessment was (active treatment = 66% female; placebo = 48% female). The
sex of participants who completed the week 12 assessment was not provided.
Inclusion criteria:
1. Agitation for at least four weeks and score >39 on the CMAI
2. NINCDS-ADRDA diagnosis of probable or possible Alzheimer’s disease,
clinical dementia rating of three
3. Resident in a specialist nursing home or NHS continuing care facility
4. Age > 60 years
5. Free of psychotropic medication (antipsychotics and/or cholinesterase
inhibitors) for at least two weeks
Exclusion criteria:
1. A known sensitivity to cholinesterase drugs
2. A disability that may have prevented them from completing the study
3. Severe, unstable or poorly controlled medical conditions
4. A history of stroke
Interventions
Intervention groups included in this review:
1. Placebo medication and active aromatherapy (lemon balm oil). N=38 allocated
to this intervention.
2. Placebo medication and placebo aromatherapy. N=39 allocated to this
intervention.
Additional intervention groups:
3. Active medication (donepezil) and placebo aromatherapy (sunflower oil). 5 mg
of donepezil a day increasing to 10 mg after 1 month. N=37 allocated to this
intervention.
The oil was administered twice a day by gently massage of the hands and upper
arms for one to two minutes for 12 weeks.
Outcomes
Outcomes included in this review:
1. Agitation: PAS
2. Behavioural symptoms: NPI
3. Adverse effects
4. Quality of life: Blau QOL scale
5. Activities of Daily Living: Barthel scale of Activities of Daily Living
Notes
Risk of bias

















"Labelling of tablet bottles and oils was carried out by an external
organization, and thus researchers and patients were blinded to the





Low risk "Assessments were carried out at baseline, week 4 and week 12 by
the research nurse who was blind to treatment group."











"Eight subjects withdrew from the study at baseline, and an additional
12 subjects withdrew before the first follow-up assessment at week 4.
Of the remaining 94, 13 had no assessment data in week 12."
Number of participants that withdrew at baseline: Donepezil = 2;
lemon balm = 3; Placebo = 3
Number of participants that withdrew before week 4 follow up:
Donepezil = 4; lemon balm = 3; Placebo = 5
Number of participants that withdrew before week 12 follow up:
Donepezil = 5, lemon balm = 2; Placebo = 6
This review included the lemon balm and placebo groups in this
review. Following attrition in the two groups, the below outlines the
percentage of data that was available.
Data available at baseline: 92%
Data available at week 4 follow up: 82%




Low risk All outcomes reported




Treatment allocation: randomised controlled trial
Study design: crossover
Intervention: Treatment one: three weeks, washout one week, Treatment two: three
weeks.
Assessments: assessments were conducted at baseline and during the weeks of oil
application. During the weeks of oil application, PAS assessments were performed
twice a day and NPI and CMAI assessments were conducted weekly.
Participants
Country: UK
Participants recruited from: inpatient ward
Number of participants randomised: The study states that 18 participants were
included in the 'final study group'
Number of participants included in analysis: The study states that 18 participants
were included in the 'final study group'
Mean age of participants: not reported
Sex of participants: not reported
Inclusion criteria:
Not reported, "all inpatients were deemed eligible for inclusion in the study ... final
study group consisted of 18 patients, all with moderate to severe dementia and
significant BPSD"
Exclusion criteria:
"Patients were excluded if they refused to consent, withdrew consent at any time, or
if their nearest relative refused to give assent"
Interventions
Interventions included in this review:
1. Aromatherapy <2% lemon balm oil
2. Placebo treatment 1% geranium and 0.5% lemon oil
Protocol:
The nursing staff gently rubbed the oil into one forearm of each patient for one-
minute, twice a day, for three weeks. This was followed by a one week washout
period before the alternative intervention was administered by rubbing the oil into one
forearm of each patient for one-minute, twice a day, for three weeks.
Outcomes Outcomes included in this review:
1. CMAI (no quantitative data reported)
2. PAS (no quantitative data reported)
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3. NPI (no quantitative data reported)
4. Adverse effects (no quantitative data reported)
Notes The trial was run twice, one year apart.
Risk of bias


















"The two groups of oils appeared very similar in terms of smell, viscosity
and texture. In a test prior to starting the trial, no member of the team










"the PAS assessments were completed twice per day by nursing staff,
and the NPI and CMAl assessments weekly by a consultant psychiatrist










High risk No data reported




Treatment allocation: randomised controlled trial
Study design: parallel group
Intervention: six weeks
Assessments: Cognitive assessment was measured at baseline and following the six
week intervention. "CMAI-SF was administered five times in the study: 1. within the
month prior to the intervention; 2. at the end of the second week of the intervention; 3.
at the end of the fourth week of the intervention; 4. at the completion of the sixth week;
and 5. six weeks after the completion of the intervention in week 12."
Participants Country: Australia
Participants recruited from: Long-term care facilities
Number of participants randomised: 67 participants
Number of participants included in analysis: 61 participants
Mean age of participants: The mean age of participants included in the analysis was
84 years, SD = 6.36 (mean age of each intervention group was not specified)
Sex of participants: The sex of participants included in the analysis was 59% females
(sex for each intervention group was not specified)
Inclusion criteria:
1. Aged 60 or over
2. Living in a participating nursing home for at least three months
3. Cognitive functional impairment indicative of a dementia condition; MMSE score of
24 out of 30 or less; and features of Alzheimer’s disease according to American
Psychiatric Association DSM-IV-TR
4. A documented history of a minimum of two weeks of agitation or aggression in total
(consecutively or 14 single days), within the past three months
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5. A documented history of physical and/or chemical restraint for agitation and
aggression, including PRN (as required) medication
6. Consent for participation from resident's family or health-attorney
7. No known allergic reaction to lavender oil
8. No recent skin tears, lacerations, bruises, or redness and swelling that might
interfere with hand massage
Exclusion criteria:
1. A diagnosis of schizophrenia or mental retardation to avoid the complication of dual
diagnoses impacting on treatment effect
2. Expected to be transferred to another residential facility within the next three months
Interventions
Intervention groups included in this review:
1. 3% lavender mist. N=23 allocated to this intervention.
2. 3% lavender mist plus hand massage twice a day for 10 days; each hand massaged
for 2.5 minutes. N=22 allocated to this intervention.
3. Water mist. N=22 allocated to this intervention.
Protocol:
The lavender mist consisted of 75 drops of pure 100% lavender oil mixed with 4 ml
essential oil solubiliser and 125 cc purified water. Three sprays of lavender/water mist
applied to the participants’ chest within a 30cm distance. All treatments were given
twice a day, at two time periods, 9 am to 11 am and 2 pm to 4 pm, seven days a week
for six weeks.
Outcomes
Outcomes included in this review:
1. Agitation: CMAI-SF (quantitative data not reported separately for each treatment
group)
2. Adverse events
3. MMSE (no data reported)
Notes
Risk of bias




















Participants were not blinded
"Participants received treatments in a quiet and private environment, such
as the participant’s room in an attempt to keep staff and family blind to the
intervention type. If necessary, curtains and folding screens were used to














"One male resident died in the first week of the study, and as no data were
collected he was excluded. Five participants or their relatives withdrew
consent for participation and data during the six weeks of the intervention
stage of the study. Withdrawal of consent was related to family wanting
reassurance their family member was in the intervention rather than
control group and the team being unable to reassure the family. The data
for these individuals was also excluded"
Selective
reporting
Low risk All relevant outcomes reported








Treatment allocation: randomised controlled trial
Study design: parallel group
Intervention: four weeks




Participants recruited from: Long-term care Sendai Tomizawa Hospital
Number of participants randomised: 28 participants
Number of participants included in analysis: 28 participants
Mean age of participants: The mean age of participants who were randomised
was 78 years, SD = 10 (active treatment = 77 years, SD = 10; no treatment = 80
years, SD = 11)
Sex of participants: The percentage of females who were randomised was 68%
females (active treatment = 64% female; no treatment = 71% female)
Inclusion criteria:
1. Dementia diagnosed according to DSM-IV criteria
2. Physical condition stable for three months
Exclusion criteria:
1. Major medical illness
Interventions
Interventions groups included in this review:
1. Two drops of lavender oil odorant (Farm Tomita, Hokkaido, Japan) was applied
to the collar of the participants underwear. Aromotherapy was administered
approximately one hour after meals, three times a day, for 4 weeks. N=14
allocated to this intervention.
2. No active treatment. N=14 allocated to this intervention.
Outcomes
Outcomes included in this review:
1. Behavioural symptoms: NPI
2. Cognition: MMSE











"We randomly assigned patients with BPSD into two groups." No






"We randomly assigned patients with BPSD into two groups." No














'a trained nurse directly observed the patient and performed the NPI,
MMSE and Barthel Index tests in a blinded manner to treatment
status'











All outcomes were reported. Data was not provided for the Barthel
Index tests, however, the study reports 'The Barthel Index did not
significantly change in both groups'.




Treatment allocation: randomised controlled trial
Study design: crossover
Intervention: acclimation: one week, first intervention: one week, second
intervention: one week. No washout period.
Assessment:
"Participants were monitored with actigraphs (Ambulatory Monitoring Inc,)
for 3 weeks."
"Weekday epochs of actigraph data (4 x 24 h, Mon noon to Fri noon)". An
average of total sleep was calculated over the 4 nights.
"Total minutes of sleep were calculated after sleep periods were manually
defined using data from sleep logs."
"Neuropsychiatric Inventory (NPI) measured every week."
Participants
Country: Minnesota
Participants recruited from: participants were residents from memory
care units in the Deer Crest assisted living facility in Red Wing, Minnesota
Number of participants randomised: 22 participants
Number of participants included in analysis: 21 participants
Mean age of participants: 85.7 years (unclear whether this was
calculated based on the participants who were randomised or the
participants who completed to study)
Sex of participants: 71% female (unclear whether this was calculated
based on the participants who were randomised or the participants who
completed to study)
Inclusion criteria: not specified
Exclusion criteria: not specified
Interventions
Interventions included in this review:
1. Lavender oil applied at bedtime to the spine, back and neck, followed by
a diffuser containing lavender oil for 20 minutes.
2. Almond oil applied at bedtime to the spine, back and neck, followed by a
diffuser containing almond oil for 20 minutes.
Outcomes
Outcomes included in this review:
1. Sleep: total sleep time in minutes and percentage of sleep (time spent
sleeping divided by the total sleep period)
2. Behavioural symptoms: NPI
Notes
Unable to find a published paper. Data extraction was conducted on poster
and abstract data only.
"This work was funded by a donation from a non-profit private foundation."
"Essential oils and diffusers were donated by Young Living, Inc."
Risk of bias




Unclear risk Limited information given, "Double-blinded, randomized-controlled cross-over trial"
Allocation concealment
(selection bias) Unclear risk
Limited information given, "Double-blinded, randomized-
controlled cross-over trial"

















Number of participants enrolled = 22
Number of participants that completed the intervention = 21
Number of participants that adhered to intervention = 17
Number of participants with a complete dataset = 11 (50%
of the data is available)
Selective reporting
(reporting bias) Low risk All stated outcomes were reported




Treatment allocation: randomised controlled trial
Study design: crossover
Intervention: treatment one: three weeks; washout: two weeks; treatment two:
three weeks
Assessments: assessments were conducted at baseline, following treatment 1,
following the washout period and following treatment 2
Participants
Country: Hong Kong, China
Participants recruited from: Care and attention homes in Hong Kong
Number of participants randomised: 70 participants
Number of participants included in analysis: 70 participants
Mean age of participants: The mean age of participants who were randomised is
78.29 years
Sex of participants: The percentage of females who were randomied is 58.6%
females
Inclusion criteria:
1. Diagnosis of dementia according to DSM-IV criteria
2. 'Clinically significant agitation' as determined by research team psychiatrist using
Chinese version of CMAI
3. Concurrent psychotropic medication was allowed. 51.4% of subjects were
receiving psychotropic medication. Their medication was not altered during the
course of the trial.
Exclusion criteria:
Interventions
Interventions included in this review:
1. 100% lavender essential oil
2. Sunflower preparation essential oil
Two drops of the oil assigned to the patient were dropped onto cosmetic cotton.
This was then placed into an aroma diffuser. Two diffusers were then placed one on
each side of the subject's pillow for at least one hour a night whilst they slept.
Outcomes
Outcomes included in this review:
1. Agitation: Chinese CMAI
2. Agitation: Chinese NPI
Notes Data for first period of cross-over has not been received for re-analysis.
Risk of bias





Low risk "Participants were randomly assigned to group A or B by blockedrandomisation", no additional information provided















"A staff in each C & A home was designated for implementing the
interventions. The same staff member was then interviewed about the
performance of study participants. It might lead to bias since they were







"A staff in each C & A home was designated for implementing the
interventions. The same staff member was then interviewed about the
performance of study participants. It might lead to bias since they were









Low risk All outcome measures were reported




Treatment allocation: randomised controlled trial
Study design: crossover
Intervention: treatment one: one week; washout: four days; treatment two: one week
Assessments: Assessments were conducted 30 minutes before application, 30
minutes after application, 60 minutes after application
Participants
Country: Australia
Participants recruited from: eight specialist psychogeriatric nursing homes and three
private nursing homes
Number of participants randomised: 66 participants
Number of participants included in analysis: 64 participants
Mean age of participants: 77.6 years, SD = 9.4 (unclear whether this was calculated
based on the participants who were randomised or the participants who completed to
study)
Sex of participants: 59% females (unclear whether this was calculated based on the
participants who were randomised or the participants who completed to study)
Inclusion criteria:
1. At least mild dementia on the Clinical Dementia Rating scale
2. Physically agitated behaviour; behaviour was not due primarily to pain, physical
illness, depression or psychosis
3. Residence in the facility for at least three months
4. Nursing and medical staff were asked not to alter participants’ psychotropic
medications if possible
5. Consent to study participation by the next of kin or guardian
Exclusion criteria:
1. An acute, life-threatening illness
2. A variable psychotropic medication regime
3. A medical condition that precluded the use of topical oils
Interventions Interventions included in this review:
1. 30% lavender in jojoba oil
2. Jojoba oil
Protocol:
A nursing staff member massaged 1 ml of either the lavender or control oil into both
forearms for one minute each, giving a total of 2 ml per session. The intervention was
conducted three times during each of the treatment periods. Aromatherapy was
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administered at times when nursing staff reported that the selected physically agitated
behaviour was most likely to be present.
Outcomes
Outcomes included in this review:
1. Overall behavioural and psychological symptoms: Observation of behaviour (data
not reported for first phase of the trial)
2. Mood: Philadelphia Geriatric Center Affect Rating Scale (PGCARS) (data not











"Participants were allocated randomly by the project manager using an
Excel random number generator to either a lavender or control study






"Participants were allocated randomly by the project manager using an
Excel random number generator to either a lavender or control study









"The lavender and control oils were stored in identical vials, marked as A
or B."
"It was not considered practicable or desirable to attempt to blind
participants, all of whom had marked cognitive impairment, to the
treatment condition."
"Only a single researcher, who had no other involvement in the study, was








"To maintain observer blinding, nurses applying the oil wore a nose clip
and research assistants, who completed the observations, applied a











Low risk Outcomes were reported




Treatment allocation: randomised controlled trial
Study design: parallel group
Intervention: four weeks (intervention administered twice weekly)
Assessments: Assessments were conducted at baseline and following the
intervention.
Participants Country: UK
Participants recruited from: patients in a district general hospital ward
Number of participants randomised: 21 participants
Number of participants included in analysis: 21 participants
Mean age of participants: 66.8 years (SD =11.5) (unclear whether this was
calculated based on the participants who were randomised or the participants who
completed to study). Mean age of intervention groups not reported.
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Sex of participants: 57% female (unclear whether this was calculated based on the
participants who were randomised or the participants who completed to study). Sex of
intervention groups not reported.
Inclusion criteria:
1. Diagnosis of severe dementia made by psychiatrist




Intervention groups included in this review
1. Lavender in a diffuser with conversation twice a week. N=7 allocated to this
intervention.
2. Lavender applied via massage twice a week. N=7 allocated to this intervention.




Outcomes included in this review:
"Behaviour was recorded using a video camera for 15 minutes across four periods of
the day (10-11 am, 11-12 noon, 2-3 pm, and 3-4 pm). A baseline measure of behaviour
was recorded over a two-week period preceding the study. Each patient's behaviour
was recorded twice in each period of the day studied, giving a total of eight records or
two hours of footage per individual. No two samples relating to any one individual were
recorded on the same day." (Data was reported at baseline but not provided following
the intervention. A reduction in motor behaviour after treatment was presented as a
figure.)
Notes Significant interaction with time.
Risk of bias








"Seven patients were randomly allocated to each of three conditions"
"Random allocation of patients was made by two authors (EI and FC),
neither of whom was involved in either data collection or data analysis"
















"The same aromatherapist administered each condition and was blind to


















High risk No useable data
Other bias Low risk No additional biases
Takahashi 2020




Treatment allocation: randomised controlled trial
Study design: parallel group
Intervention: eight weeks
Assessments: Assessments were conducted at baseline, following four weeks of the
intervention, and following eight weeks of the intervention
Participants
Country: Japan
Participants recruited from: not specified
Number of participants randomised: not specified
Number of participants included in analysis: 36 participants
Mean age of participants: experimental group= 76.2 years, SD = 9.8 years. Control
group = 75.8 years, SD = 7.8 years.
Sex of participants: experimental group = 63% female, control group = 59% female
Inclusion criteria:
1. Diagnosis of Alzheimer's disease according to NINCDS/ADRA. Patients with
probable Alzheimer's disease were included.
Exclusion criteria:
1. Patients with mild cognitive impairment
2. Patients with olfactory dysfunctions
Interventions
Intervention groups included in this review:
1. Ethanol with cedar fragrance. N=19 allocated to this intervention.
2. Ethanol without cedar fragrance. N=17 allocated to this intervention.
Cedar leaves were added to ethanol solution, the solution was then distilled. Each day,
2.3mL of the distilled solution (with or without cedar) was used as a room fragrance
(diffused using rattan sticks) in the residents' space (living room and bedroom). A few
times a day, the distilled solution (with or without cedar) was also sprayed as a mist on
the patients' clothing and bedding.
Outcomes
Outcomes included in this review:
1. Behavioural symptoms: NPI
2. Cognition: Alzheimer's Disease Assessment Scale-cognitive subscale
3. Cargiver burden: Japanese version of the Zarit Caregiver Burden interview
Notes
Risk of bias






























Unclear risk No information provided.








Low risk All outcomes were reported.




Treatment allocation: randomised controlled trial
Study design: crossover
Intervention: 14 day consecutive intervention treatment, followed by a 14 day wash
out period, before commencing the next treatment. Three treatments were
administered to each participant.
Assessments: NPI and CMAI was measured before and after each treatment cycle
Participants
Country: Sydney, Australia
Participants recruited from: Six Residential Aged Care Facilities (RACF)
Number of participants randomised: 56 participants with dementia, 19 participants
without dementia
Number of participants included in analysis: 39 participants with dementia, 10
participants without dementia.
Mean age of participants: mean age of all participants included in the analysis is
89.31 years, SD = 6.30. The study does not provide the mean age for just the subjects
with dementia.
Sex of participants: percentage female of all of the participants included in the
analysis is 75.5%. The study does not provide the sex for just the subjects with
dementia.
Inclusion criteria:
1. Age 65 years or older
2. Lived full time in the RACF for three months
3. A cognitive level of moderate or higher as demonstrated by a score above 10 on the
MMSE
4. Agitated behaviours recorded on at least one of the Aged Care Funding Instruments
(ACFI) behaviour domains
5. At least one agitated behaviour with a frequency of at least six occurrences
observed by the nurse in the last two weeks, assessed on the NPI at baseline
6. An ability to detect scent as demonstrated in a scent test at screening
7. A valid signed resident or carer consent form
8. Participants stable on regular antipsychotic medication who exhibited observable
agitation were included in this trial
Exclusion criteria:
1. A diagnosis of psychosis or agitation resulting from brain damage
2. The presence of an acute life-threatening condition as reported by staff or the
medical
officer
3. Any condition that was likely to confound the study such as Schizophrenia,
Parkinsons disease or another medical condition as determined by the researcher to
interfere with interpretation of study results.
Interventions
Interventions included in this review:
Participants were randomly assigned a treatment sequence of lavender, lemon balm
and sunflower oil. 'The RA applied two drops of oil from the correctly assigned scent
bottle to a 25 mm x 20 mm dark 100% cotton patch and attached the cloth to the
participants collar area. The patch was dark in colour to obscure essential oil
pigmentation. The RA did not engage in any non deliberate conversation with the
participant and removed the patch after 2 hours.
Outcomes Outcomes included in this review:
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'The allocation sequence was concealed until data collection was
completed and analysis finalised.'
'Assigned treatments were blinded in 6 bottles labeled with the letters A-F.
A second researcher accessed the computer-generated assignment of
each participant. Each participant was allocated a corresponding essential
oil bottle letter for each treatment cycle. When the group assignment was
confirmed the researcher informed the primary investigator of the assigned
treatment to be implemented in each treatment period. Assigned









Study does not specify that the participants were blinded.
'The RA was blinded to the allocation group and treatment by a nose peg



















Low risk All outcome measures were reported.




Treatment allocation: cluster-randomised controlled trial
Study design: parallel group
Intervention: four weeks
Assessments: CMAI was measured at baseline, following the four week intervention
and three weeks after the end of the intervention
Participants Country: Taiwan
Participants recruited from: Six institutions that specialise in the care of dementia
patients (Three retirement homes for veterans and three long-term care facilities)
Number of participants randomised: 186 participants, of whom 130 were
randomised to the two groups included in this review.
Number of participants included in analysis: 130 participants were included in the
analysis of the two groups included in this review
Mean age of participants: active treatment = 83.67 years, SD = 4.96. Control group
= 81.56 years, SD = 6.79.
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Sex of participants: The percentage of females who were randomised to the two
groups included in this review is 30% female (active treatment = 34% female;
placebo = 24.6% female)
Inclusion criteria:
1. Fulfill the DSM-IV standard for dementia as diagnosed by psychiatrists or
neurologist
2. Score 35 or above on the long form of the CMAI, defined as severe agitation
3. Expected to be present in the long-term care facility every Monday to Friday during
the period of the study




Intervention groups included in this review:
1. 2.5% lavender oil was applied for two minutes at five acupoints. A warm-up
exercise was completed for five minutes. The protocol was conducted once per day,
for five days per week, for a total of four weeks. N=73 allocated to this intervention.
2. No intervention, daily care routine was conducted as usual. N=57 allocated to this
intervention.
Additional intervention groups:
3. Each acupoint was pressed for two minutes with 2.5% lavender oil at five
acupoints. A warm-up exercise was completed for five minutes. The protocol was
conducted once per day, for five days per week, for a total of four weeks. N=56.
Outcomes
Outcomes included in this review:
1. Agitation: CMAI-Chinese version
Additional outcomes:
1. Agitation: heart rate variability analyzer (Heart rate variability was considered in the
paper to be a measure of agitation, however, this outcome has been excluded from
this review as it is not an established or recognised measurement of agitation.)
Notes
Risk of bias








Each time, an institution in the veteran home was randomly assigned to
the aroma- acupressure, aromatherapy, or control group and so was an
institution in the long term care facility. The research assistant was
































Low risk No protocol. All outcomes were appropriately discussed.




Possible recruitment bias before or after cluster allocation. Possible
analysis bias as the study does not specify whether clustering was taken




Treatment allocation: randomised control trial
Study design: parallel group
Intervention: eight weeks (intervention conducted between weeks two-nine of
study)
Assessments: assessments conducted at week one (baseline) and 24 hours after
massage in weeks two, five and nine
Participants
Country: Taiwan
Participants recruited from: five long-term care facilities
Number of participants randomised: 59 participants
Number of participants included in analysis: 56 participants
Mean age of participants: In the text, the mean age for the participants who were
randomised is stated as ‘92 years, SD = 7 years’ which is assumed to be a
typographical error. (Experimental group = 83.34 years, SD = 6.41; control group =
80.67 years, SD = 7.44)
Sex of participants: The percentage of females who were randomised is 61%
female (experimental group = 65.5% female; control group = 56.7% female)
Inclusion criteria:
1. Mild to severe dementia (SPMSQ score ≤8 or MMSE ≤17 if high school education
or MMSE ≤23 if high school education or higher).
2. Demonstrated agitation or depressive symptoms in the past two weeks as
reported by caregivers using the CCMAI and CSDD-C (no cut off point was
specified).
Exclusion criteria:
1. Severity of behavioural problems prohibited interaction with researchers.
Interventions
Intervention groups included in this review:
1. 3 drops of lavender oil and 3 drops of orange oil were added to 5ml of essential
oil. The aromatherapy oil was massaged around the neck, shoulders and arms for
30 minutes, once per week. The intervention was performed by trained research
assistants. N=29 allocated to this intervention.
2. No intervention, usual care was provided ‘participation in regular activities (e.g.
group singing, watching movies) in the long-term care facilities’. N=30 allocated to
this intervention.
Outcomes
Outcomes included in this review: 
1. Agitation: CCMAI (measured at baseline and within 24 hours of the massage in
weeks two, five and nine)
2. Mood: CSDD-C (measured at baseline and within 24 hours of the massage in
weeks two, five and nine)
Notes
Registry entry (NCT02126059)
Further information sought from authors on 04/11/18 - the authors did not respond.
Quality of life: WHO Quality of Life-brief Taiwanese version (WHOQOL-BREF) was
an outcome mentioned in the trial registry but was not mentioned in the paper.
Risk of bias







Block technique not explained. Conducted solely by primary author.
“Individuals with dementia were randomly assigned to the control or
intervention groups through a randomized block technique performed by













risk No information but probably not possible to blind













2 participants did not complete the study in the intervention group. Data
available in the intervention group: 93%
1 participant did not complete the study in the control group. Data




High risk WHO-QOL-BREF not reported, although listed in trial registry entry
Other bias Low risk Part of a larger trial. No mention of how care facilities implementingaromatherapy were selected.
[2] BPSD - behavioural and psychological symptoms in dementia
CDR - Clinical Dementia Rating Scale
CMAI - Cohen Mansfield Agitation Inventory
CSDD-C - Cornell Scale for Depression in Dementia-Chinese Version
PAS - Pittsburgh Agitation Scale
NINCDS-ADRDA - National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disorders Association 
NPI - Neuropsychiatric Inventory
SD - standard deviation
QOL - quality of life
Characteristics of excluded studies [ordered by
study ID]
Study Reason for exclusion
Akhondzadeh
2003 Wrong intervention (oral administration of lemon balm extract)
Bowles 2002 Wrong study design (not RCT)
Brooker 1997 Wrong study design (not RCT)
Burleigh 1997 Wrong study design (not RCT)





Cooper 2012 Systematic review
Dimitriou 2018 Wrong study design (no control group)
Farokhnia 2014 Wrong intervention
Fung 2012 Systematic review
Fung 2018 Wrong intervention
Gray 2002 Wrong study design (not RCT)
Guendling 2010 Wrong study design
Henry 1993 Wrong study design
Holmes 2002 Wrong study design
Jimbo 2009 Wrong study design
Kaufmann 2011 In vitro study
Kaymaz 2017 Wrong study design (not RCT)
Kilstoff 1998 Wrong study design (not RCT)
Kimura 2013 Wrong study design (not RCT)
Klages 2011 Wrong intervention
Korn 2012 Wrong intervention
Li 2017 Wrong study design (not RCT)
Lucian 2012 Animal study
MacMahon 1998 Wrong study design (not RCT)
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Study Reason for exclusion
Mitchell 1993 Very limited methodological information. Very limited results. Probably wrongparticipants ("dementia-related disorders").
Moss 2003 Wrong participants
NCT02518243 Wrong study design (not RCT)
Ogun-Semore
2019 Wrong study design (no control group)
Opie 1999 Literature review
Pengelly 2012 Wrong intervention
Sakamoto 2012 Wrong participants
Snow 2004 Wrong study design (not RCT)
Tsolaki 2016 Wrong participants
UMIN000019044 Wrong study design (dose comparison)
UMIN000027692 Wrong study design (dose comparison)
UMIN000027693 Wrong study design (not RCT)
Watanabe 2010 Wrong participants
West 1994 Wrong study design (not RCT)
Wolfe 1996 Wrong study design (not RCT)
Woods 1996 Wrong intervention
Zalomonson
2019 Wrong study design (not RCT)
Characteristics of studies awaiting classification
[ordered by study ID]
ISRCTN86563511
Methods
Treatment allocation: randomised controlled trial
Study design: not specified
Intervention: 12 weeks
Assessments: conducted at baseline and following 12 week intervention
Participants Country: Australia
Participants recruited from: resident in nursing home
Number of participants: not specified - target number of participants was 100-130
people.
Mean age of whole study population: not specified
Sex of whole study population: not specified
Inclusion criteria:
1. Have been living in the nursing home for more than three months
2. Be more than 65 years old
3. Already be on an aromatherapy care plan; or deemed by the Director of Care or the
care staff to be unlikely to be disturbed by the use of the aromatherapy lotion in place
of their normal skin integrity lotion
4. Have English as their first language
5. A Mini-Mental State Examination (MMSE) score of 10-26
6. A diagnosis of dementia, short-term memory loss or cognitive impairment that is not
caused by any other diagnosis of mental illness
7. Residents with non-acute concomitant diseases may participate if their disease is
medically controlled.
Exclusion criteria:
1. Had a myocardial infarction or stroke in previous three months
2. Epilepsy
3. Current treatment with anti-cholinesterase or anti-cholinergic drugs
4. Eczema, psoriasis or dermatitis around the neck and shoulders area
5. Known allergy to Eucalyptus, Cypress, Ginger, Lemongrass, Lime or Mandarin
essential oils or aqueous cream
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6. An adverse reaction to treatment patch-tests given during screening process
7. Vision or hearing impairments that prevent them from undertaking the cognitive test
Interventions
Intervention groups relevant to this review:
1. The 'active' treatment will contain 1 ml each of cypress (Cupressus sempervirens),
lime (Citrus latifolia) and eucalyptus (Eucalyptus globulus) essential oils, diluted in a
non-fragranced aqueous cream lotion
2. The 'inactive' preparation will contain 1 ml each of ginger (Zingiber officinalis),
lemongrass (Cymbopogon citratus) and mandarin (Citrus reticulata) essential oils,
diluted in a non-fragranced aqueous cream lotion
3. The placebo preparation will contain only non-fragranced aqueous cream lotion and
will be used during the washout periods. An important purpose of the placebo is to
control for the possible effect of touch
Outcomes
Outcomes relevant to this review:
1. Primary: MMSE
2. Secondary: NOSGER (Nurses' Observation Scale for Geriatric Patients)
Notes
Despite repeated attempts, CDCIG have been unable to get any reply from the study




Treatment allocation: randomised controlled trial
Study design: parallel group
Intervention: not specified
Assessments: "3 time points"
Participants
Country: Hong Kong
Participants recruited from: not specified
Number of participants randomised: 112 participants
Number of participants included in analysis: not specified
Mean age of participants: not specified
Sex of participants: not specified
Inclusion criteria:
1. 60 years of age or older
2. Have a CMMSE score below 18 if illiterate, 19 if they have one to two years of
education, and 20 if they had more than two years of education
3. Reported to have BPSD
4. Willing to participate in the research, with informed consent signed by their guardian
or carer
Exclusion criteria:
1. Allergic to essential oils
2. Refused to give consent
3. Over-sensitive to tactile stimulation
4. Have a history of kidney or liver disease
5. Have ever had an epileptic seizure
Interventions









4. Chinese version of the Barthel Index
Additional outcomes
5. Chinese version of the index of social engagement
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Notes Registry entry. Study completion date 2018. No published paper identified. Contacted




Treatment allocation: randomised controlled trial
Study design: parallel groups
Intervention: not specified
Assessments: Baseline, day four, day seven, day 13
Participants
Country: Switzerland
Participants recruited from: not specified "the acute geriatric ward"
Number of participants randomised: 32 participants
Number of participants included in analysis: not specified
Mean age of participants: not specified
Sex of participants: not specified
Inclusion criteria:
1. Patients admitted to the acute geriatric ward
2. Patients with a known diagnosis of dementia associated with BPSD or diagnosis
performed during hospitalisation
3. 70 years or older
Exclusion criteria:
1. Patients with alcohol-based dementia
2. Patients with Mild Cognitive Impairment
3. Patients with language barrier
4. Patients already being treated with aromatherapy
Interventions
Intervention groups relevant to this review:
1. Diffusion aromatherapy (lavender essential oil / wild orange essential oil)
2. No intervention
Outcomes
Outcomes relevant to this review:
1. NPI-Nursing Home Version
Notes
Registry entry. Study completion date 2018. No published paper identified. Contacted




Treatment allocation: randomised control trial
Study design: crossover
Intervention: 12 weeks (Group one: six week aroma hand massage followed by six
week live as usual; Group two: six week live as usual followed by six week aroma hand
massage)
Assessments: assessments conducted prior to the first intervention/live as usual,
following the first six week intervention/live as usual and following the second six week
intervention/live as usual.
Participants Country: Japan
Participants recruited from: not specified
Number of participants randomised: not specified
Mean age of whole study population: The study planned to recruit participants aged
between 20 - 80 years old. Exact ages are not specified.
Sex of whole study population: The study planned to recruit males and females.
Percentages of males and females are not specified.
Inclusion criteria:
1. Those who live around Matsuyama or Toon, Ehime Japan
2. Aged over 65 years old
3. Those who can participate in the trial in pairs of couples or friends
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4. Those who can come to the examination for themselves
5. Those who are interested in preventing dementia or improving cognitive function
6. Following explanation of the trial, those who agree with participation and give written
informed consent
Exclusion criteria:
1. Those who have severe heart disease
2. Those who have severe hypertension (180/110 mmHg or more)
3. Those who have severe arrhythmia
4. Those who are pregnant
5. Those who have other severe diseases
Interventions
Intervention groups relevant to this review:
Group one. First examination - then aromatherapy hand massage for 10 minutes prior
to sleeping at home (duration 6 weeks). Second examination - followed by living as
usual (duration not specified). Final examination.
Group two. First examination, followed by living as usual (duration not specified).
Second examination - then an aromatherapy hand massage for 10 minutes prior to
sleeping at home (duration 6 weeks). Final examination.
Outcomes
Outcomes relevant to this review:
Cognitive function
Notes
Registry entry. Recruitment closed 2015. No published paper identified. Mixed
population, including participants with dementia. Authors asked if trial competed and if
data available for participants with dementia only. The author did not respond.
UMIN000026366
Methods
Treatment allocation: randomised control trial
Study design: parallel group
Intervention: three months
Assessments: before and after the intervention
Participants
Country: Japan
Participants recruited from: not specified
Number of participants randomised: not specified
Mean age of whole study population: The study planned to recruit participants aged
between 60-85 years old. Exact ages are not specified.
Sex of whole study population: The study planned to recruit males and females.
Percentages of males and females are not specified.
Inclusion criteria:
1. Males and females who live around Matsuyama city
2. Aged 60 - 85 years
3. Those who are able to join in the initial and final examination
4. Those who can perform the intervention daily at home and are able to join the aroma
foot massage class (6 sessions) on their own
5. Those who are interested in the prevention of dementia or other disease, or
promotion of health
6. Those who joined in the explanation session for participation in this study and gave
written informed consent
Exclusion criteria:
1. Those who participated in the cognitive function improvement effect of aromatherapy
massage research study in 2015 and 2016
2. Those who have severe cardiac disease
3. Those who have severe hypertension (>180/110)
4. Those who have severe arrhythmia
5. Those who have other severe diseases
6. Those who have allergy about the aroma oil (examined by patch test)
For criteria two to five, participation was permitted if symptoms were stable (due to
medication) or a doctor provided consent.
Interventions Intervention groups relevant to this review:
1. Participants in the experimental group received 10 minutes of aroma foot massage
daily for three months. Did not specify who administers the intervention.
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2. The control group lived as usual
Outcomes
Outcomes relevant to this review:
Cognitive function:
1. The Montreal Cognitive Assessment (MoCA)
2. Digit Symbol Substitution Test (DSST)
Notes
Registry entry. No published paper identified. Mixed population, including participants
with dementia. Authors have been contacted and asked if trial is completed and if data
available for participants with dementia only. The author did not respond.
Yoshiyama 2015
Methods
Treatment allocation: randomised controlled trial
Study design: crossover
Intervention: first oil administered for four weeks, followed by a four week washout
interval, followed by the second oil administered for four weeks
Assessments: assessments were conducted before and after each trial and four
weeks after the study
Participants
Country: Nara, Japan
Participants recruited from: a nursing home
Number of participants randomised: 14 participants
Mean age of whole study population: 82.8 years, SD = 9.503 years
Sex of whole study population: 100% female
Inclusion criteria:
1. Residence in the nursing home
2. Aged 65 years or older
3. Dementia diagnosed by the International Classification of Diseases 10th revision
4. Mild-to-moderate dementia (score of 10-26 on the MMSE)
5. Score of III on the Independence Degree of Daily Living for the Demented Elderly
scale
6. Negative reaction on a patch test with jojoba oil and Delight & Harmony oil (D&H oil)
7. Consent for participation from patients and their families
Exclusion criteria:
1. Any acute physical illness
Interventions
Intervention groups relevant to this review:
1. D&H oil (1.02% essential oils and 0.2% lavender oil) (3ml of oil was used for both
hands)
2. Jojoba oil (3ml of oil was used for both hands)
Protocol:
The first oil was administered three times per week for four weeks, with a four-week
washout interval, followed by the second oil administered three times per week for four
weeks. The oil was massaged gently on one hand and then the other in the following
order: forearm, wrist, palm, fingers, and back of the hand.
Treatment administered in the living room of the nursing home by a single researcher
and aroma therapist, in the afternoon.
Outcomes
Outcomes unable to use in the review (insufficient information provided):
1. Depression: CSDD
2. Agitation: CMAI (assess the frequency of agitated behavioural disturbance)
3. Degree of psychiatric symptoms and care burdens: NPI-Q
4. Activities of daily living in dementia: Functional Independent Measure (FIM)
(measuring the degree of disabilities and assistance required in ADLs). A single
researcher evaluated the effect on BPSD and also ADLs.
Notes
Paper has been published in the Journal of Alternative and Complementary Medicine.
The results provided in the published paper are unclear. Authors have been asked to
provide raw data for all outcomes. The author did not respond. Aromatic wellness
supplied the certified organic massage oil (Delight & Harmony oil).
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Characteristics of ongoing studies [ordered by
study ID]
ACTRN12617001159347
Study name The effectiveness of topical essential oils for agitation in dementia: a cluster-randomised, placebo-controlled feasibility trial
Methods
Treatment allocation: cluster-randomised controlled trial
Study design: parallel
Intervention: eight weeks
Assessments: CMAI, PAS and QoL-AD were measured in weeks zero, four, eight and
10. Frequency of adverse events were measured in weeks one, four and eight. Study
feasibility was measured in week 10.
Participants
Country: Australia
Participants recruited from: postcodes in Australia (5600 - Whyalla, 5245 - Hahndorf,
5245 - Mannum, 5253 - Murray Bridge)
Number of participants randomised: accrual to date = 25 participants
Mean age of whole study population: not specified
Sex of whole study population: not specified
Inclusion criteria:
1. Has been a resident of the study site for a period of at least four weeks.
2. Has a diagnosis of dementia (as determined by Mini-Mental State Examination
(MMSE), DSM-IV criteria or medical diagnosis).
3. Has clinically significant agitation (as defined by a score of 39 or greater on the
CMAI, or a score of four or greater on the Pittsburgh Agitation Scale [PAS])
4. Can provide informed consent, both directly (if appropriate) and via their next of kin.
5. Minimun age 40
Exclusion criteria:
1. Concurrent exposure to essential oils in any form
2. Concurrent exposure to other novel therapeutic interventions for agitation (e.g. Paro,
Play up)
3. History of significant head trauma or brain lesions
4. Known allergy or sensitivity to any of the ingredients in the active or control
interventions.
Interventions
1. Intervention: Participants in the intervention group will receive a bespoke blend of
essential oils (4.5%) in a cream base, and a bespoke blend of essential oils (3%) in an
oil base, at a dose of 20mls three times daily (for the cream), and 10 mls three times
daily, as required (for the oil), for eight consecutive weeks; the intervention will be
administered topically (i.e. forearms/face/neck/shoulders for the cream [depending on
participant preference], and lower legs for the oil) by trained nursing staff. Each blend
will be personalised based on the participant’s odour preference, unique presentation
of symptoms, and health history (including known sensitivities and contraindications to
any oils or their chemical constituents). The interventions will be blended by a trained
aromatherapist, who will select up to five appropriate essential oils from a list of 38
hypoallergenic oils. Fidelity will be assessed using a medication record, and by noting
the remaining volume of cream in the intervention receptacle at weeks four (mid-
intervention) and eight (post-intervention).
2. Control: Participants in the control group will receive control cream (cream base
only) and control oil (oil base only), at a dose of 20mls three times daily (for the cream),
and 10 mls three times daily, as required (for the oil), for eight consecutive weeks; the
control treatment will be administered topically (i.e. forearms/face/neck/shoulders for
the cream [depending on participant preference], and lower legs for the oil) by trained
nursing staff. Fidelity will be assessed using a medication record, and by noting the
remaining volume of cream in the control receptacle at weeks four (mid-intervention)
and eight (post-intervention).
Outcomes Primary Outcomes:
1. Mean Cohen Mansfield Agitation Inventory (CMAI) score
2. Mean Pittsburgh Agitation Scale (PAS) score
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Secondary Outcomes:
1. Mean Quality of Life – Alzheimer’s Disease scale (QoL-AD) score
2. Mean frequency of use of PRN antipsychotic medication (as reported on the PAS)
3. Mean frequency of use of physical restraint (as reported on the PAS)
4. Frequency of adverse events (e.g. erythema, pruritus; measured using a
standardised adverse event record)




Department of Rural Health
University of South Australia
111 Nicolson Avenue
Whyalla Norrie, SA, 5608
Australia
matthew.leach@unisa.edu.au
Notes Authors have been contacted to provide further information. The author did notrespond.
ChiCTR-INR-17013281
Study name Comparison of the effects of aroma-laser acupuncture and aromatherapy ondepression in dementia patients
Methods
Treatment allocation: randomised parallel controlled trial
Study design: parallel
Intervention: not specified
Assessments: conducted at baseline and following the intervention
Participants
Country: Taiwan, China
Participants recruited from: long term care facilities: St. Joseph Home (Hsinchu
County) & Suang Lien Elderly Center (New Taipei City)
Number of participants randomised: Not specified. Target is 41 in each of the three
experimental groups.
Mean age of whole study population: not specified
Sex of whole study population: not specified
Inclusion criteria:
1. Dementia case (MMSE less than 23)
2. Living in LTC facility during study period
3. The cases who GDS-SF15 great than five points
4. The case's arms and legs doesn't have any infection or injury.




1. Aroma-laser acupuncture group: limonene is applied to acupoints then used the
portable laser acupuncture device
2. Aromatherapy group: limonene is used with massage




Outcomes were measured by the assistant.
Starting date
Date of registration: 2017-11-07




13F, 368 Dayeh Road, Taipei, Taiwan, China
mhyang@ym.edu.tw
Notes
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Authors have been contacted to provide further information. The author did not
respond.
[3] CDCIG - Cochrane Dementia and Cognitive Impairment Group
CMAI - Cohen Mansfield Agitation Inventory
MMSE - Mini-Mental State Examination
NOSGER - Nurses' Observation Scale for Geriatric Patients
Appendices
Appendix 1. Update searches: January 2012,






[Date of most recent search: 5 May 2020]
Keyword search: aroma OR
aromatherapy OR lemon OR rose OR














2. MEDLINE In-Process and other non-indexed
citations and MEDLINE 1950-present (OvidSP)








7. (lewy* adj2 bod*).mp.
8. deliri*.mp.
9. (chronic adj2 cerebrovascular).mp.
10. ("organic brain disease" or "organic
brain syndrome").mp.




13. (cerebr* adj2 deteriorat*).mp.
14. (cerebral* adj2 insufficient*).mp.
15. (pick* adj2 disease).mp.




20. ((cognit* or memory* or mental*)























26. exp Complementary Therapies/
27. "alternative therap*".mp.
28. exp Complementary Therapies/
29. "essential oil*".mp.
30. aroma*.ti,ab.
31. ("lemon balm" or "rose* oil*" or
"lavender oil*").mp.
32. or/22-31
33. 21 and 32
34. randomized controlled trial.pt.






41. (animals not (humans and
animals)).sh.
42. 40 not 41
43. 42 and 33 
 
3. EMBASE
1980-2018 May 8 (OvidSP)








8. (lewy* adj2 bod*).mp.
9. deliri*.mp.
10. (chronic adj2 cerebrovascular).mp.
11. ("organic brain disease" or "organic
brain syndrome").mp.
12. "supranuclear palsy".mp.




15. (cerebr* adj2 deteriorat*).mp.
16. (cerebral* adj2 insufficient*).mp.
17. (pick* adj2 disease).mp.
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22. CADASIL.mp.
23. ((cognit* or memory* or mental*)












34. ("lemon balm" or "rose* oil*" or
"lavender oil*").mp.
35. or/25-34
36. 35 and 24
37. randomized controlled trial/






44. 36 and 43
 
4. PsycINFO
1806-May week 2 2019 (OvidSP)
[Date of most recent search: 5 May 2020]
1. exp Dementia/
2. exp Delirium/
3. exp Huntingtons Disease/
4. exp Kluver Bucy Syndrome/
5. exp Wernickes Syndrome/
6. exp Cognitive Impairment/
7. dement*.mp.
8. alzheimer*.mp.
9. (lewy* adj2 bod*).mp.
10. deliri*.mp.
11. (chronic adj2 cerebrovascular).mp.
12. ("organic brain disease" or "organic
brain syndrome").mp.
13. "supranuclear palsy".mp.




16. (cerebr* adj2 deteriorat*).mp.
17. (cerebral* adj2 insufficient*).mp.
18. (pick* adj2 disease).mp.
















23. ("parkinson* disease dementia" or
PDD or "parkinson* dementia").mp.
24. ((cognit* or memory* or mental*)











34. ("lemon balm" or "rose* oil*" or
"lavender oil*").mp.
35. or/26-34






42. 25 and 35 and 41
 
5. CINAHL (EBSCOhost)
[Date of most recent search: 5 May 2020]
S1 (MH "Dementia+") 
S2 (MH "Delirium") or (MH "Delirium,
Dementia, Amnestic, Cognitive
Disorders") 
S3 (MH "Wernicke's Encephalopathy") 
S4 TX dement*
S5 TX alzheimer*
S6 TX lewy* N2 bod* 
S7 TX deliri*
S8 TX chronic N2 cerebrovascular 
S9 TX "organic brain disease" or
"organic brain syndrome"
S10 TX "normal pressure
hydrocephalus" and "shunt*" 
S11 TX "benign senescent
forgetfulness"
S12 TX cerebr* N2 deteriorat*
S13 TX cerebral* N2 insufficient*
S14 TX pick* N2 disease 




S19 S1 or S2 or S3 or S4 or S5 or S6 or
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S13 or S14 or S15 or S16 or S17 or
S18 
S20 TX "aroma therap*" 
S21 ("Aromatherapy") or (MH
"Aromatherapy") 
S22 TX "complementary therap*"
S23 (MH "Alternative Therapies") 
S24 TX "alternative therap*" 
S25 TX "essential oil*" 
S26 AB aroma*
S27 AB "lemon balm" OR "rose* oil*"
OR "lavender oil*" 
S28 S20 or S21 or S22 or S23 or S24
or S25 or S26 or S27 
S29 S19 and S28 
S30 AB random*
S31 AB placebo 
S32 (MH "Clinical Trials+") 
S33 AB groups 
S34 TX trial*
S35 S30 or S31 or S32 or S33 or S34 
S36 S29 and S35 
6. Web of Knowledge – all databases
[Date of most recent search: 5 May 2020]
Topic=("lemon balm" OR "rose* oil*" OR
"lavender oil*" OR aroma* OR
aromatherapy OR "essential oil*") AND
Topic=(dementia* OR alzheimer* OR
BPSD OR lewy OR "cognit* impair*" OR
MCI OR VCI OR AD) AND Topic=
(randomly OR placebo OR groups OR
trial OR RCT OR randomized OR
randomised OR "double-blind*" OR















[Date of most recent search: 5 May 2020]
aroma OR aromatherapy OR lemon OR
limão OR limón OR lavender OR
lavanda OR alfazema OR "essential
oil$" [Words] and dementia OR
alzheimer OR demência OR demencia
OR cognición OR cognição OR











8. CENTRAL (The Cochrane Library) (Issue 5 of
12, 2018)
[Date of most recent search: 5 May 2020]
#1 MeSH descriptor Dementia explode
all trees
#2 MeSH descriptor Delirium, this term
only
#3 MeSH descriptor Wernicke
Encephalopathy, this term only
#4 MeSH descriptor Delirium,
Dementia, Amnestic, Cognitive



















#10 "organic brain disease" or "organic
brain syndrome"
#11 "normal pressure hydrocephalus"
and "shunt*"








#20 (#1 OR #2 OR #3 OR #4 OR #5 OR
#6 OR #7 OR #8 OR #9 OR #10 OR
#11 OR #12 OR #13 OR #14 OR #15






#26 "lemon balm" or "rose* oil*" or
"lavender oil*"
#27 MeSH descriptor Aromatherapy
explode all trees
#28 MeSH descriptor Complementary
Therapies explode all trees
#29 (#21 OR #22 OR #23 OR #24 OR
#25 OR #26 OR #27 OR #28)
#30 (#29 AND #20)
 
9. Clinicaltrials.gov (www.clinicaltrials.gov)
[Date of most recent search: 5 May 2020]
Interventional Studies | dementia OR
alzheimers OR AD OR alzheimer's OR
alzheimer OR lewy OR FTLD OR FLD
OR MCI OR cognitive OR cognition |
aroma OR aromatherapy OR lavender











10. ICTRP Search Portal
(http://apps.who.int/trialsearch) [includes:
Australian New Zealand Clinical Trials Registry;
ClinicalTrilas.gov; ISRCTN; Chinese Clinical Trial
Registry; Clinical Trials Registry – India; Clinical
Research Information Service – Republic of
Korea; German Clinical Trials Register; Iranian
Registry of Clinical Trials; Japan Primary
Registries Network; Pan African Clinical Trial
Registry; Sri Lanka Clinical Trials Registry; The
Netherlands National Trial Register]
[Date of most recent search: 15 May 2019]
Databse not available 5 May 2020
(Interventional Studies | dementia OR
alzheimers OR AD OR alzheimer's OR
alzheimer OR lewy OR FTLD OR FLD
OR MCI OR cognitive OR cognition |
aroma OR aromatherapy OR lavender










8/17/2020 Cochrane Dementia and Cognitive Improvement Group: Aromatherapy for dementia
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fversion%3Dz2007011022199407474470262434096… 60/87



























Appendix 2. Update search: May 2010
Source Search strategy Hits
MEDLINE In-Process and other non-indexed








7. (lewy* adj2 bod*).mp.
8. deliri*.mp.
9. (chronic adj2 cerebrovascular).mp.
10. ("organic brain disease" or "organic brain
syndrome").mp.
11. ("normal pressure hydrocephalus" and
"shunt*").mp.
12. "benign senescent forgetfulness".mp.
13. (cerebr* adj2 deteriorat*).mp.
14. (cerebral* adj2 insufficient*).mp.
15. (pick* adj2 disease).mp.




20. ((cognit* or memory* or mental*) adj3
(declin* or impair* or los* or deteriorat*)).mp.
134







26. exp Complementary Therapies/
27. "alternative therap*".mp.
28. exp Complementary Therapies/
29. "essential oil*".mp.
30. aroma*.ti,ab.
31. ("lemon balm" or "rose* oil*" or "lavender
oil*").mp.
32. or/22-31
33. 21 and 32
34. randomized controlled trial.pt.






41. (animals not (humans and animals)).sh.
42. 40 not 41
43. 42 and 33
44. (2008* or 2009* or 2010*).ed.
45. 43 and 44
EMBASE








8. (lewy* adj2 bod*).mp.
9. deliri*.mp.
10. (chronic adj2 cerebrovascular).mp.
11. ("organic brain disease" or "organic brain
syndrome").mp.
12. "supranuclear palsy".mp.
13. ("normal pressure hydrocephalus" and
"shunt*").mp.
14. "benign senescent forgetfulness".mp.
15. (cerebr* adj2 deteriorat*).mp.
16. (cerebral* adj2 insufficient*).mp.
17. (pick* adj2 disease).mp.
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23. ((cognit* or memory* or mental*) adj3











34. ("lemon balm" or "rose* oil*" or "lavender
oil*").mp.
35. or/25-34
36. 35 and 24
37. randomized controlled trial/






44. 36 and 43
45. (2008* or 2009* or 2010*).em.
46. 44 and 45
PsycINFO




4. exp Kluver Bucy Syndrome/
5. exp Wernickes Syndrome/
6. exp Cognitive Impairment/
7. dement*.mp.
8. alzheimer*.mp.
9. (lewy* adj2 bod*).mp.
10. deliri*.mp.
11. (chronic adj2 cerebrovascular).mp.
12. ("organic brain disease" or "organic brain
syndrome").mp.
13. "supranuclear palsy".mp.
14. ("normal pressure hydrocephalus" and
"shunt*").mp.
15. "benign senescent forgetfulness".mp.
16. (cerebr* adj2 deteriorat*).mp.
17. (cerebral* adj2 insufficient*).mp.
18. (pick* adj2 disease).mp.
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23. ("parkinson* disease dementia" or PDD or
"parkinson* dementia").mp.
24. ((cognit* or memory* or mental*) adj3










34. ("lemon balm" or "rose* oil*" or "lavender
oil*").mp.
35. or/26-34






42. 25 and 35 and 41
43. (2008* or 2009* or 2010*).up.
44. 42 and 43
CINAHL (EBSCOhost) S1 (MH "Dementia+")
S2 (MH "Delirium") or (MH "Delirium,
Dementia, Amnestic, Cognitive Disorders")  
S3 (MH "Wernicke's Encephalopathy")  
S4 TX dement*
S5 TX alzheimer*
S6 TX lewy* N2 bod* 
S7 TX deliri*
S8 TX chronic N2 cerebrovascular  
S9 TX "organic brain disease" or "organic
brain syndrome"
S10 TX "normal pressure hydrocephalus" and
"shunt*"
S11 TX "benign senescent forgetfulness"
S12 TX cerebr* N2 deteriorat* 
S13 TX cerebral* N2 insufficient* 
S14 TX pick* N2 disease  
S15 TX creutzfeldt or jcd or cjd  
S16 TX huntington*  
S17 TX binswanger* 
S18 TX korsako*
S19 S1 or S2 or S3 or S4 or S5 or S6 or S7
or S8 or S9 or S10 or S11 or S12 or S13 or
S14 or S15 or S16 or S17 or S18  
S20 TX "aroma therap*"  
37
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S21 ("Aromatherapy") or (MH
"Aromatherapy")  
S22 (MH "Alternative Therapies")  
S23 (MH "Alternative Therapies")  
S24 TX "alternative therap*"  
S25 TX "essential oil*"  
S26 AB aroma* 
S27 AB "lemon balm" OR "rose* oil*" OR
"lavender oil*"  
S28 S20 or S21 or S22 or S23 or S24 or S25
or S26 or S27  
S29 S19 and S28  
S30 AB random*
S31 AB placebo  
S32 (MH "Clinical Trials+")  
S33 AB groups  
S34 TX trial*
S35 S30 or S31 or S32 or S33 or S34  
S36 S29 and S35  
S37 EM 2008  
S38 EM 2009  
S39 EM 2010  
S40 S37 or S38 or S39  
S41 S36 and S40  
Web of Science with Conference Proceedings
(1945 to present)
Topic=(dement* OR alzheimer* OR lewy OR
deliri* OR cerebro* OR creutzfeldt OR
huntington* OR korsako* OR binswanger*)
AND Topic=(aroma* OR "complementary
therap*" OR "essential oil*" OR "lemon" OR
"rose oil*" OR lavender) AND Topic=(trial OR
random* OR placebo OR groups)
Timespan=Latest 5 years
112
LILACS (South and Central American coverage) aroma$ [Words] and demen$ OR alzheimer$[Words] 1
ALOIS (for a list of what ALOIS covers:
http://www.medicine.ox.ac.uk/alois/content/about-
alois)
aromatherapy OR lemon OR lavender OR
rose OR aroma OR alternative therapies OR
complementary therapies
12
Umin (Clinical Trial register of Japan) aromatherapy OR lemon OR lavender ORrose OR aroma 0
CENTRAL (The Cochrane Library) #1 MeSH descriptor Dementia explode all
trees
#2 MeSH descriptor Delirium, this term only
#3 MeSH descriptor Wernicke
Encephalopathy, this term only
#4 MeSH descriptor Delirium, Dementia,






#10 "organic brain disease" or "organic brain
syndrome"
#11 "normal pressure hydrocephalus" and
"shunt*"
60
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#20 (#1 OR #2 OR #3 OR #4 OR #5 OR #6
OR #7 OR #8 OR #9 OR #10 OR #11 OR #12




#23  "alternative therap*"
#24 "essential oil*"
#25 aroma*
#26 "lemon balm" or "rose* oil*" or "lavender
oil*"
#27 MeSH descriptor Aromatherapy explode
all trees
#28                MeSH descriptor
Complementary Therapies explode all trees
#29 (#21 OR #22 OR #23 OR #24 OR #25
OR #26 OR #27 OR #28)
#30 (#29 AND #20), from 2008 to 2010
Clinicaltrials.gov
Interventional Studies | aromatherapy OR
lemon OR lavender OR rose OR aroma |
received from 01/01/2008 to 05/17/2010
19
ICTRP Search Portal which covers: ANZCTR;
ClinicalTrials.gov; ISRCTN; Chinese ClinicalTrial
Registry; India Clinical Trials Registry; German
Clinical Trials Register and more.
ADVANCED SEARCH: (dementia OR
alzheimers OR lewy OR cognitive OR
cerebrovascular) AND (aromatherapy OR
lemon OR lavender OR rose OR aroma) AND




Total after first-assess and de-duplication by TSC 8
Appendix 3. Update search: March 2008
Source Search strategy Hits





“aroma therap*” OR “complementary therap*” OR “alternative therap*” OR
“essential oil*”
AND
Phases 1-3 of the Highly sensitive search strategies for identifying reports of
randomized controlled trials in Medline (APPENDIX 5b, Cochrane Handbook,









“aroma therap*” OR “complementary therap*” OR “alternative therap*” OR
“essential oil*”
AND
Phases 1-3 of the Highly sensitive search strategies for identifying reports of
randomized controlled trials in Medline (APPENDIX 5b, Cochrane Handbook,
2006), all terms searched as Title, abstract, keyword, Publication type.
49

















LILACS terms for trials
0
Total 83
Total after first-assess and de-duplication by TSC 2
Appendix 4. Previous version of the methods
Methods  
Criteria for considering studies for this review  
Types of studies  
This review considered all relevant randomized controlled trials (RCTs). Owing to the
nature of aroma therapy double-blinding may not be possible when combined with
informed consent. A minimum length of trial and requirements for a follow-up were
not inclusion criteria.
Types of participants  
Participants in included studies were to have a diagnosis of dementia of any type
and severity, based on diagnostic criteria such as ICD-10 (WHO 1993) and DSM-IV
(APA 1994), or well validated assessment scales for cognitive function, such as the
MMSE (Folstein 1975) and ADAS-Cog (Rosen 1994).
Types of interventions  
This review considered trials using fragrance from plants, in an intervention defined
as aroma therapy, for people with dementia. All doses, frequencies, and fragrances
were considered.
Types of outcome measures  









Search methods for identification of studies  
Electronic searches  
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We searched ALOIS (www.medicine.ox.ac.uk/alois) - the Cochrane Dementia and
Cognitive Improvement Group’s Specialized Register on 26 November 2012. The
search terms used were: aromatherapy, lemon, lavender, rose, aroma, alternative
therapies, complementary therapies, essential oils.
ALOIS is maintained by the Trials Search Co-ordinator of the Cochrane Dementia
and Cognitive Improvement Group and contains studies in the areas of dementia
prevention, dementia treatment and cognitive enhancement in healthy. The studies
are identified from:  
1. Monthly searches of a number of major healthcare databases: Medline,
Embase, Cinahl, Psycinfo and Lilacs
2. Monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial
Register); the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the
Chinese Clinical Trials Register; the German Clinical Trials Register; the
Iranian Registry of Clinical Trials and the Netherlands National Trials Register,
plus others)
3. Quarterly search of The Cochrane Library’s Central Register of Controlled
Trials (CENTRAL)
4. Six-monthly searches of a number of grey literature sources: ISI Web of
Knowledge Conference Proceedings; Index to Theses; Australasian Digital
Theses
To view a list of all sources searched for ALOIS see About ALOIS on the ALOIS
website.
Details of the search strategies used for the retrieval of reports of trials from the
healthcare databases, CENTRAL and conference proceedings can be viewed in the
‘methods used in reviews’ section within the editorial information about the Dementia
and Cognitive Improvement Group.
Additional searches were performed in many of the sources listed above to cover the
timeframe from the last searches performed for ALOIS to ensure that the search for
the review was as up-to-date and as comprehensive as possible. The search
strategies used can be seen Appendix 1.
Electronic searches carried out in the previous version(s) of the review can be
viewed in Appendix 2 and Appendix 3.
In addition the following online journals were searched: 'Complementary Therapies in
Medicine', and 'Complementary Therapies in Nursing and Midwifery'.
Searching other resources  
'Experts' in the field of complementary therapies were contacted to identify ongoing
and unpublished research as well as the Aroma Therapy Organisations Council.
Selection of trials
LMT and AS independently screened the titles and abstracts extracted by the
searches for their eligibility for potential inclusion in the review based on the above
criteria, which were discussed with MO.
Update Sept. 2008: FEH and TPHB assessed the new study found by the March
2008 search using the same criteria as that previously used.
Data collection
Data were extracted from the published reports and unpublished company reports.
The summary statistics required for each trial and each outcome for continuous data
are the mean change from baseline, the standard error of the mean change, and the
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number of patients for each treatment group at each assessment. Where changes
from baseline were not reported, the mean, standard deviation and the number of
patients for each treatment group at each time point were extracted if available. For
binary data the numbers in each treatment group and the numbers experiencing the
outcome of interest were sought. The baseline assessment is defined as the latest
available assessment prior to randomization, but no longer than two months prior.
For each outcome measure, data were sought on every patient assessed. To allow
an intention-to-treat analysis (ITT), the data were sought irrespective of compliance,
whether or not the patient was subsequently deemed ineligible, or otherwise
excluded from treatment or follow-up. If ITT data were not available an analysis of
patients who completed treatment was conducted. For continuous or ordinal
variables which can be approximated to continuous variables, the main outcomes of
interest were the assessment score at the time point being considered and the
change from the baseline (i.e. pre-randomization or at randomization) at this time
point. For some binary and ordinal outcomes the endpoint category relative to
baseline category was the outcome of interest. For other categorical outcomes, such
as the Clinical Global Impression of Change (CIBIC-Plus), the endpoint itself was of
clinical relevance as all patients had begun, by definition, at the same baseline
score. The baseline assessment score was the latest available score, no longer than
two months prior to the randomization. Studies may have included a titration period
prior to the randomization phase of the study. The data from these non-randomized
titration periods were not used to assess safety or efficacy since patients were not
randomized, nor was treatment or dose allocation concealed. Data from any open
follow-on phase, after the randomized phase, were not used to assess safety or
efficacy for the same reasons.
Quality assessment
A checklist for assessing the quality of all studies identified was developed, as
presented below.
Checklist for assessing methodological quality.
Does the paper include:
1) A thorough review of the literature?
2) Hypothesis formulation/aims/power analysis?
3) Details of informed consent?
4) Description/justification of sampling procedure?
5) Description/justification of design (for non RCTs)?
6) Justification of lack of controls (for non RCTs)?
7) Details of randomization method(s) (selection bias)?
8) Number/details of drop-outs (attrition bias)?
9) Description/justification/standardization of outcome measures?
10) Blind assessment/details of assessor(s) (detection bias)?
11) Clearly presented results (appropriate statistics)?
12) A description of limitations of study/design (for non RCTs)?
13) Intention to treat analysis?
14) Suggestions for future research?
Data analysis
Summary statistics (n, mean and standard deviation) were required for each rating
scale at each assessment time for each treatment group in each trial for change from
baseline.
When change from baseline results are not reported, the required summary statistics
were calculated from the baseline and assessment time treatment group means and
standard deviations. In this case a zero correlation between the measurements at
baseline and assessment time was assumed. This method overestimates the
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standard deviation of the change from baseline, but this conservative approach is
considered to be preferable in a meta-analysis.
For binary outcomes, such as clinical improvement or no clinical improvement, the
odds ratio was used to measure treatment effect.
For continuous or ordinal variables, such as psychometric test scores, clinical global
impression scales, functional and quality of life scales, there are two possible
approaches. If ordinal scale data appear to be approximately normally distributed or
if the analysis that the investigators perform suggests parametric tests were
appropriate, then the outcome measures were treated as continuous data. The
second approach, which may not have excluded the first, was to concatenate into 2
categories which best represent the contrasting states of interest, and to treat the
variable as binary. For binary outcomes such as institutionalization and death, the
endpoint itself was of interest and the Peto method of the typical odds ratio was
used.
A weighted estimate of the typical treatment effect across trials was calculated.
Overall estimates of the treatment difference are presented. In all cases the overall
estimate from a fixed-effect model is presented and a test for heterogeneity using I2
statistic performed. Where there is evidence of heterogeneity of the treatment effect
between trials then either only homogeneous results are pooled, or a random-effects
model is used (in which case the confidence intervals would be broader than those of
a fixed-effect model).
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CMAI total (change from baseline at 4
weeks)
-11.08
(3.62) -3.06 0.022 -19.95 TO -2.21 Aromatherapy
CMAI physical aggression (change from
baseline at 4 weeks)
-3.27
(1.78) -1.84 0.115 -7.62 TO 1.80 -
CMAI physical non-aggressive (change
from baseline at 4 weeks)
-5.36
(1.42) -3.77 0.009 -8.84 TO -1.88 Aromatherapy
CMAI verbal aggression (change from
baseline at 4 weeks)
-0.39
(0.49) -0.80 0.456 -1.58 TO 0.81 -
CMAI verbal non-aggressive (change
from baseline at 4 weeks)
-2.92
(0.91) -3.22 0.018 -5.14 TO -0.70 Aromatherapy
NPI total (change from baseline at 4
weeks)
-15.80
(3.50) -4.51 0.004 -24.37 TO -7.22 Aromatherapy
NPI agitation (change from baseline at 4
weeks)
-2.31
(0.89) -2.59 0.041 -4.50 TO -0.12 Aromatherapy
NPI aberrant motor behaviour (change
from baseline at 4 weeks)
-3.01
(1.23) -2.45 0.050 -6.02 TO 0.00 Aromatherapy
CMAI - Cohen Mansfield Agitation Inventory
NPI - Neuropsychiatric Inventory
Table 2
Baseline characteristics for each group (Ballard 2002)
VARIABLE CONTROL TREATMENT
Age 79.7 (8.5) 77.2 (7.6)
CMAITOT 60.6 (16.6) 68.3 (15.0)
NPITOT 34.9 (15.0) 37.6 (17.6)
Number taking atypical neuroleptic medication 12/36 16/36
Number taking benzodiazepine 19/36 16/36
Number taking antidepressant medication 7/36 19/36
Number taking neuroleptic medication 18/36 23/36
Number taking other psychotropic medication 12/36 14/36
Number taking any psychotropic medication 33/36 33/36
Number taking cognitive enhancer 0/36 1/36
CMAITOT - Cohen Mansfield Agitation Inventory Total score
NPITOT - Neuropsychiatric Inventory Total score
Figure 1
Study flow diagram.
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Figure 2
Risk of bias graph: review authors' judgements about each risk of bias item presented as
percentages across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figure 3
Risk of bias summary: review authors' judgements about each risk of bias item for each
included study.


























































































































































Ballard 2002 + + + + + + +
Burns 2011 + + + + + + +
Cameron 2011 + + + + ? - +
Fu 2013 + + + + + + +
Fujii 2008 ? ? - + + + +
Hanson 2013 ? ? + + - + -
Lin 2007 + ? - - + + +
O'Connor 2013 + + + + + + +
Smallwood 2001 ? ? ? + + - +
Takahashi 2020 ? ? ? ? ? + +
Watson 2019 ? + + ? - + +
Yang 2015 ? ? ? + + + ?
Yang 2016 ? ? ? + + - +
Analysis 1.1
Comparison 1: Aromatherapy versus placebo, Outcome 1: Agitation, mean change (CMAI,
high score=bad)
Agitation, mean change (CMAI, high score=bad)
Study Mean difference SE Aromatherapy N Placebo N Mean difference (95%CI)
Ballard 2002 -11.1 4.5409 35 36 -11.10 [-20.00, -2.20]
Analysis 1.2
Comparison 1: Aromatherapy versus placebo, Outcome 2: Behavioural symptoms, mean
change (NPI, high score=bad)
Behavioural symptoms, mean change (NPI, high score=bad)
Study Mean difference SE Aromatherapy N Placebo N Mean difference (95%CI)
Ballard 2002 -15.8 4.3878 35 36 -15.80 [-24.40, -7.20]
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Please can you edit the abstract of the review?
In the abstract, it is not clear what outcomes you looked for, how many studies you
found, how many studies are included and what the results are. The Plain Language
Summary provides more information than the abstract.
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